Document:

EX-10.21

 Exhibit 10.21 
 Confidential Materials omitted and filed separately with the 
 Securities and
Exchange Commission. Double asterisks denote omissions. 
 Execution Version 

LICENSE AGREEMENT 
 This LICENSE AGREEMENT is entered into this 7th day of January, 2008 (the “EFFECTIVE DATE”) between The University of North Carolina at Chapel Hill having an address at Campus Box 4105, 308 Bynum Hall, Chapel Hill, North Carolina, 27599-4105
(“UNIVERSITY”) and Epizyme, Inc., a corporation organized and existing under the laws of the State of Delaware having its principal office/place of business c/o MPM Capital L.P. at The John Hancock Tower, 200 Clarendon Street, 54th Floor,
Boston, MA 02116 (“LICENSEE”). 
 WITNESSETH 

WHEREAS, UNIVERSITY owns and controls valuable technologies related to epigenetic screening methods and biological materials identified
in the UNIVERSITY files listed below (collectively “INVENTIONS”): 
  

	 	•	 	 [**] (UNIVERSITY file: [**]) 

  

	 	•	 	 [**] (UNIVERSITY file: [**]) 

  

	 	•	 	 [**] (UNIVERSITY file: [**]) 

  

	 	•	 	 [**] (UNIVERSITY file: [**]) 

  

	 	•	 	 [**] (UNIVERSITY file: [**]) 

  

	 	•	 	 [**] (UNIVERSITY file: [**]) 

  

	 	•	 	 [**] (UNIVERSITY file: [**]); and 

 WHEREAS, INVENTIONS were developed by Yi Zhang (“ZHANG”) and colleagues (together with ZHANG, the “INVENTOR(S)”) at UNIVERSITY; and 

WHEREAS, ZHANG is an employee of the Howard Hughes Medical Institute (“HHMI”), and HHMI has assigned its right in INVENTIONS
funded by HHMI to UNIVERSITY, so therefore the applicable terms of this LICENSE AGREEMENT must be consistent with HHMI policy; and 
 WHEREAS, UNIVERSITY is interested in licensing its information, materials and technology concerning the INVENTIONS in a manner that will benefit the public, and the grant of a license best facilitates the
distribution of useful products and the utilization of new processes; and 
 WHEREAS, LICENSEE desires to obtain a license to
use INVENTIONS as herein provided and commits to using commercially reasonable efforts (either itself or through AFFILIATES or sublicensees) and resources in a program of commercializing products and processes based upon or embodying said INVENTIONS
under the terms and conditions set forth herein; 

 NOW, THEREFORE, in consideration of the premises and mutual promises and covenants contained
in this LICENSE AGREEMENT and for good and valuable consideration, it is agreed by and between UNIVERSITY and LICENSEE as follows: 
 ARTICLE 1: DEFINITIONS 
 1.1 “AFFILIATE” means (a) any
person or entity which owns or controls at least fifty percent (50%) of the equity or voting stock of LICENSEE, or (b) any person or entity fifty percent (50%) of whose equity or voting stock is owned or controlled by LICENSEE, or
(c) any person or entity of which at least fifty percent (50%) of the equity or voting stock is owned or controlled by the same person or entity owning or controlling at least fifty percent (50%) of the equity or voting stock of
LICENSEE. 
 1.2 “BIOLOGICAL MATERIALS” means any proprietary biological materials developed at UNIVERSITY by
INVENTOR(S) (a) as of the Effective Date and which are necessary or useful for practicing the PATENT RIGHTS or INVENTIONS, including without limitation the biological materials described on Appendix A, and (b) during the term of this
Agreement, solely to the extent necessary for practicing the PATENT RIGHTS or INVENTIONS. For clarity, BIOLOGICAL MATERIALS excludes any PATENT RIGHTS. 
 1.3 “COMPANY PRODUCTS” means any therapeutic or diagnostic product (1) that contains as an active ingredient a compound that was initially identified, or whose structure belongs to
the same chemical series as a compound that was initially identified, by LICENSEE as a result of LICENSEE’s use of BIOLOGICAL MATERIALS or PATENT RIGHTS, (2) whose manufacture, sale, or intended use is covered by at least one valid,
unexpired, enforceable claim in a patent owned or licensed by LICENSEE in the country of sale, and (3) whose manufacture, sale, or use is not covered by any VALID CLAIM in PATENT RIGHTS. 

1.4 “CONFIDENTIAL INFORMATION” means all confidential or proprietary information of a party hereto, including without
limitation, information related to such party’s products, processes, techniques, technology, formulae, research data, manufacturing methods, know-how, trade secrets, customers, suppliers, information relating to sales and profits and other
financial data. For clarity, CONFIDENTIAL INFORMATION of UNIVERSITY includes UNIVERSITY TECHNOLOGY and unpublished patent applications, and CONFIDENTIAL INFORMATION of LICENSEE includes any information or reports disclosed to UNIVERSITY pursuant to
Article 4. 
 1.5 “EQUITY SECURITIES” means the common shares of LICENSEE, any other capital shares of LICENSEE
(including preferred shares), and any securities of LICENSEE that are convertible into any capital shares of LICENSEE. 
 1.6
“LICENSED FIELD” means, and is limited to, the practice and use of PATENT RIGHTS, UNIVERSITY TECHNOLOGY and/or BIOLOGICAL MATERIALS for discovery, development, manufacture and/or commercialization of all therapeutic, prophylactic
and/or diagnostic products. 

  
 2 

 1.7 “LICENSED PRODUCTS” means any method or process, composition, product,
or component part thereof, the manufacture, use and/or sale of which is covered in whole or in part by a VALID CLAIM contained in PATENT RIGHTS. For clarity, LICENSED PRODUCTS excludes COMPANY PRODUCTS. 

1.8 “LICENSED TERRITORY” means worldwide. 
 1.9 “NET SALES” means the total invoiced sales price less any charges for (a) sales, use and other taxes, tariffs, duties, excise and other governmental charges (other than a tax on
income) levied on the sale, transportation or delivery of LICENSED PRODUCTS and actually paid, (b) shipping, packaging, postage and insurance charges, (c) allowances for returned or defective goods, rebates, credits, chargebacks or
retroactive price reductions, (d) trade, quantity and cash discounts, (e) inventory management fees paid to wholesalers and distributors, (f) discounts paid under discount prescription drug programs and reductions for coupon and
voucher programs, (g) negotiated payments made to private sector and government third party payors (e.g., PBMs, HMOs and PPOs) and purchasers/providers (e.g., staff model HMOs, hospitals and clinics), regardless of the payment mechanism,
including without limitation rebate, chargeback and credit mechanisms, and (h) portions of gross amounts billed or invoiced that are written off as uncollectible (it being understood that such amounts shall be credited against future royalties
payable hereunder or refunded to LICENSEE, as applicable). LICENSED PRODUCTS will be considered sold when billed out, when delivered or when paid for before delivery, whichever first occurs. Sales or transfers of LICENSED PRODUCTS among LICENSEE and
its AFFILIATES and sublicensees for the purpose of subsequent resale to third parties shall not be included in NET SALES; with respect to such sales or transfers, the gross amounts billed or invoiced in connection with the subsequent resale to third
parties will be included in the calculation of NET SALES. Use of any LICENSED PRODUCT in clinical trials (including compassionate use or similar programs), pre-clinical studies or other research or development activities, or disposal or transfer of
LICENSED PRODUCTS for a bona fide charitable purpose or purposes of a sampling program shall not give rise to any NET SALES. 

Notwithstanding the foregoing, in the event that LICENSED PRODUCTS are sold by LICENSEE as part of a combination product or bundled
product, the NET SALES of such product, for the purposes of determining royalty payments due under this LICENSE AGREEMENT, shall be determined by multiplying the NET SALES (as originally defined above) of the combination product by the fraction
A/(A+B), where A is the average sale price of the LICENSED PRODUCT when sold separately in finished form and B is the average sale price of the other product(s) or system sold separately in finished form, so that A+B is the average sale price of the
product(s) and, if applicable, the delivery system together, as the case may be. In the event that such average sale price cannot be determined for both the LICENSED PRODUCT and such other product(s) or system(s) in combination, NET SALES for the
purposes of determining royalty payments with respect to such combination or bundled product shall be commercially reasonable and determined by good faith negotiation between UNIVERSITY and LICENSEE. If UNIVERSITY and LICENSEE are unable to agree on
such determination within [**] days, the dispute shall be submitted to arbitration for resolution pursuant to Section 12.10. However, in no event shall the foregoing reduce NET SALES by an amount greater than [**]percent ([**]%). 

1.10 “PATENT RIGHTS” means any United States patents and/or patent applications covering INVENTIONS owned or controlled
by UNIVERSITY prior to or during the term of 

  
 3 

 
this LICENSE AGREEMENT, as well as any continuations, continuations-in-part (to the extent of claims specifically addressed to subject matter described in the patents and patent applications
listed in Appendix A), divisionals, provisionals, continued prosecution applications, or reissues thereof, and any foreign counterpart of any of the foregoing, including without limitations the patent applications listed in Appendix A, as it may be
amended from time to time by mutual agreement of the parties to reflect the foregoing definition. 
 1.11 “UNIVERSITY
TECHNOLOGY” means any unpublished research and development information, know-how, and technical data in the possession of INVENTOR(S) as of the Effective Date which relates to and is necessary or useful for the practice of INVENTIONS,
excluding BIOLOGICAL MATERIALS and PATENT RIGHTS. 
 1.12 “VALID CLAIM” means a claim of (a) an issued and
unexpired patent, which claim has not been held invalid, unpatentable or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid,
unpatentable or unenforceable through abandonment, re-examination or disclaimer, opposition procedure, nullity suit or otherwise, or (b) any pending patent application that has not been withdrawn, canceled, abandoned or disclaimed, and is not
pending more than [**] years after the earliest claimed priority date of the application. 
 ARTICLE 2: GRANT OF LICENSE

 2.1 UNIVERSITY hereby grants to LICENSEE and its AFFILIATES, to the extent of the LICENSED TERRITORY, a non-exclusive
right and license to use UNIVERSITY TECHNOLOGY in the LICENSED FIELD, with the right to sublicense as set forth in Article 6, provided that each such sublicense is granted concurrently with the grant of a sublicense to PATENT RIGHTS to the same
sublicensee. 
 2.2 UNIVERSITY hereby grants to LICENSEE and its AFFILIATES to the extent of the LICENSED TERRITORY an exclusive
license under PATENT RIGHTS covering INVENTIONS described in UNIVERSITY files [**] and a non-exclusive license under the PATENT RIGHTS covering INVENTIONS described in UNIVERSITY files [**], in each case to practice such PATENT RIGHTS in the
LICENSED FIELD, including to research, develop, make, have made, use, offer for sale, sell and import LICENSED PRODUCTS and/or COMPANY PRODUCTS in the LICENSED FIELD, with the right to sublicense as set forth in Article 6. UNIVERSITY further agrees
that it will not grant additional licenses to PATENT RIGHTS to any third parties. In the event that the non-exclusive license granted to Novartis Pharmaceuticals, Inc. (“NOVARTIS”) to practice the PATENT RIGHTS covering the INVENTIONS
described in UNIVERSITY files [**] terminates or expires, the non-exclusive licenses granted to LICENSEE under this Section 2.2 below shall convert automatically into an exclusive license grant. 

2.3 UNIVERSITY hereby grants to LICENSEE and its AFFILIATES to the extent of the LICENSED TERRITORY a non-exclusive license to possess,
use and make BIOLOGICAL MATERIALS in the LICENSED FIELD, with the right to sublicense as set forth in Article 6. Notwithstanding the foregoing, UNIVERSITY agrees that it will not grant additional licenses in the LICENSED FIELD to any third parties
to possess, use and make BIOLOGICAL MATERIALS for any commercial purposes or uses. UNIVERSITY further agrees to transfer BIOLOGICAL MATERIALS requested by LICENSEE to LICENSEE within [**] days of any such request, provided that such requests are
reasonable. 

  
 4 

 2.4 UNIVERSITY retains the right, on behalf of itself and all other non-profit academic
research institutions, to practice the PATENT RIGHTS and use the BIOLOGICAL MATERIALS and UNIVERSITY TECHNOLOGY for any non-profit purpose, including sponsored research and collaborations. 

2.5 HHMI has a paid-up, non-exclusive, irrevocable license to practice the PATENT RIGHTS and use the BIOLOGICAL MATERIALS and UNIVERSITY
TECHNOLOGY relating to UNIVERSITY files [**] for HHMI’s research purposes, but with no right to assign or sublicense. 

2.6 In the event that in any one year period as indicated in LICENSEE’s written annual summary report pursuant to Section 4.1,
LICENSEE a) does not practice under at least one of the PATENT RIGHTS or use at least one of the BIOLOGICAL MATERIALS and b) there are no active sublicenses to PATENT RIGHTS or BIOLOGICAL MATERIALS, this LICENSE AGREEMENT shall become non-exclusive
upon written notice by UNIVERSITY of such deficiency if LICENSEE fails to remedy such deficiency within [**] days following such notice. Any conversion to a non-exclusive LICENSE AGREEMENT shall constitute UNIVERSITY’s sole remedy, and
LICENSEE’s sole liability, with respect to any unremedied deficiency by LICENSEE under this Section 2.6. 

	2.7	UNIVERSITY shall be free to publish UNIVERSITY TECHNOLOGY as it sees fit. 

 2.8 Notwithstanding anything in this LICENSE AGREEMENT to the contrary, (1) any and all licenses and other rights granted hereunder are limited by and subject to the rights and requirements of the
United States Government which arise out of its sponsorship of the research which led to the conception or reduction to practice of INVENTIONS files covered by PATENT RIGHTS and/or incorporating BIOLOGICAL MATERIAL. The United States Government is
entitled, as a right, under the provisions of 35 U.S.C. §§ 200-212 and applicable regulations of Title 37 of the Code of Federal Regulations, to a non-exclusive, nontransferable, irrevocable, paid-up license to practice or have practiced
for or on the behalf of the United States Government any of PATENT RIGHTS throughout the world; 
 2.9 LICENSEE shall obtain no
implied license rights to UNIVERSITY TECHNOLOGY, BIOLOGICAL MATERIALS or PATENT RIGHTS. Any rights not expressly granted to LICENSEE shall be retained by UNIVERSITY. 
 ARTICLE 3: CONSIDERATION 
 3.1 License Fee. Within the earlier of
[**] days following the EFFECTIVE DATE or the consummation of the INITIAL FINANCING (as defined in Section 5.1), LICENSEE will pay a license fee in the form of the reimbursement of costs incurred as of the EFFECTIVE DATE (including
attorney’s fees) arising out of the patenting of INVENTIONS in the amount of [**] dollars ($[**]). Such reimbursement of patenting costs shall be non-refundable and shall not be a credit against any other amounts due hereunder except as may be
provided for elsewhere in this LICENSE AGREEMENT. 

  
 5 

 3.2 Equity. 
 3.2.1 As further consideration for the rights granted to LICENSEE under this LICENSE AGREEMENT, within [**] days following the EFFECTIVE DATE, LICENSEE will issue directly to the University of North
Carolina Foundation, Inc. (the “FOUNDATION”) on behalf of UNIVERSITY that number of shares of common stock of LICENSEE equal to [**] percent ([**]%) of the total number of issued and outstanding EQUITY SECURITIES of LICENSEE on the
EFFECTIVE DATE (“INITIAL ISSUANCE”). LICENSEE shall issue additional shares of LICENSEE’s common stock to FOUNDATION on a pro rata basis, such that FOUNDATION’s ownership of outstanding common stock of LICENSEE shall not fall
below [**] percent ([**]%) of LICENSEE’s issued and outstanding EQUITY SECURITIES, as calculated after giving effect to the anti-dilutive issuance. Such issuances shall continue after the INITIAL ISSUANCE until such time as LICENSEE shall have
received an aggregate of [**] Dollars ($[**]) in cash in exchange for LICENSEE’s EQUITY SECURITIES (the “TRIGGER FINANCING”). After the TRIGGER FINANCING has occurred, no additional shares shall be due to FOUNDATION or UNIVERSITY
pursuant to this Section 3.2.1. For purposes of illustration, if LICENSEE achieves the TRIGGER FINANCING as a result of the sale of shares of capital stock in a single transaction having an aggregate purchase price of $[**], FOUNDATION is
granted antidilution protection hereunder only on the first $[**] of such shares (i.e., FOUNDATION’s shareholdings will be diluted with respect to the additional shares of capital stock sold for $[**] on such date). 

3.2.2 At all times, LICENSEE common stock held by the FOUNDATION shall be subject to a stock purchase agreement in the form set forth in
Appendix B (the “STOCK PURCHASE AGREEMENT”), which UNIVERSITY shall cause FOUNDATION to enter into upon LICENSEE’s issuance of such common stock to FOUNDATION hereunder. The UNIVERSITY shall cause FOUNDATION to enter into reasonable
or customary agreements required by any future equity investors regarding subjecting their shares of LICENSEE common stock to rights of first refusal and co-sale, such rights to terminate on an initial public offering of LICENSEE stock pursuant to
the Securities Act of 1933, as amended. 
 3.2.3 LICENSEE shall provide to UNIVERSITY (i) within [**] days following the
EFFECTIVE DATE a capitalization table indicating the total number of issued and outstanding shares of LICENSEE’s common stock on the EFFECTIVE DATE and the total number of LICENSEE’s other EQUITY SECURITIES on the EFFECTIVE DATE and
(ii) within [**] days following the closing of TRIGGER FINANCING a capitalization table indicating the total number of issued and outstanding shares of LICENSEE’s common stock immediately after closing of TRIGGER FINANCING and the total
number of LICENSEE’s other EQUITY SECURITIES; each such capitalization table calculated on a fully diluted basis. 
 3.2.4
In the case where LICENSEE’s EQUITY SECURITIES issued to the FOUNDATION are restricted from resale in compliance with SEC Rule 144 or otherwise as required by law, LICENSEE agrees to remove or cancel the notice of restriction associated with
such shares or securities within [**] days of the request of UNIVERSITY provided that any legally required terms of restriction on resale have expired and UNIVERSITY shall have provided such information as is reasonably requested by LICENSEE or
LICENSEE’s counsel to ensure compliance with Rule 144. 

  
 6 

 3.3 Royalty Payments. Beginning on the EFFECTIVE DATE of this LICENSE AGREEMENT and
continuing for the life of this LICENSE AGREEMENT, LICENSEE will pay UNIVERSITY a running royalty of [**] percent ([**]%) of all NET SALES of LICENSED PRODUCTS by LICENSEE, its AFFILIATES and/or LICENSEE’s or its AFFILIATES’ sublicensees.
LICENSEE shall pay to UNIVERSITY said royalties on LICENSED PRODUCTS concurrently with the making of quarterly written reports as provided in Section 4.2 below. For clarity, no multiple royalties on NET SALES of a LICENSED PRODUCT shall be
payable to UNIVERSITY on a single LICENSED PRODUCT, regardless of whether its development, manufacture, use, lease, import, export, offer for sale, sale or practice is or shall be covered by more than one of the PATENT RIGHTS. 

Notwithstanding the foregoing, if LICENSEE obtains (or has obtained) one or more licenses under patents or patent applications owned by a
third party as reasonably necessary to avoid infringement thereof by the development, manufacture, use, lease, import, export, distribution, offer for sale, and/or sale of any LICENSED PRODUCT, or as reasonably necessary to avoid
infringement-related litigation with respect to such patent(s), in either case as determined by LICENSEE in its sole discretion, and the total royalty burden owed by LICENSEE to all of its licensors with respect to such LICENSED PRODUCT exceeds
[**]percent ([**]%) of LICENSEE’s aggregate NET SALES for such LICENSED PRODUCT, then LICENSEE may deduct [**] percent ([**]%) of all payments made to such third party to license such patents or patent applications, from the royalty owing to
UNIVERSITY for NET SALES of that LICENSED PRODUCT under this Section 3.3, provided that in no event shall the royalties otherwise due UNIVERSITY be less than [**] percent ([**]%) of the royalties that would be payable to UNIVERSITY were
UNIVERSITY the sole licensor with respect to such LICENSED PRODUCT. 
 3.4 Milestone Payments. LICENSEE shall make the
following milestone payments for COMPANY PRODUCTS or LICENSED PRODUCTS, as the case may be, within [**] days following the occurrence of each event specified below: 
  

					
	 (a)
	  	[**]	  	[**]
	 (b)
	  	[**]	  	[**]
	 (c)
	  	[**]	  	[**]
	 (d)
	  	[**]	  	[**]
	 (e)
	  	[**]	  	[**]
	 (f)
	  	[**]	  	[**]
	 (g)
	  	[**]	  	[**]

  
 7 

 The milestones set forth in clauses (a) through (e) above shall be payable only
once upon achievement of such milestone by LICENSEE, its AFFILIATES’ and/or LICENSEE’s or its AFFILIATES’ sublicensees, regardless of the number of COMPANY PRODUCTS and/or LICENSED PRODUCTS developed or commercialized by LICENSEE, its
AFFILIATES and/or LICENSEE’s or its AFFILIATES’ sublicensees. Each of the milestones set forth in clauses (f) and (g) shall be payable only with respect to the grant of a sublicense by LICENSEE or its AFFILIATES, as the case may
be, to a non-AFFILIATE sublicensee and not with respect to the grant of any further sublicenses by any non-AFFILIATE sublicensee of LICENSEE or of its AFFILIATES. 
 3.5 All fees, royalties, and other payments due to UNIVERSITY under this LICENSE AGREEMENT shall be made in United States Dollars. If any conversion of foreign currency to United States Dollars is
required in connection with such payments due, such conversion shall be made by using the conversion rate existing in the United States (as reported in The Wall Street Journal) on the last business day of the reporting period to which such
payments relate. If The Wall Street Journal ceases to be published or if the parties agree otherwise, then the rate of exchange to be used shall be that reported in such other business publication of national circulation in the United States
as the parties reasonably agree. In the event that, by reason of applicable laws or regulations in any country, it becomes impossible or illegal for LICENSEE or its AFFILIATES, or LICENSEE’s or its AFFILIATES’ sublicensees, to transfer, or
have transferred on its behalf, royalties or other payments to UNIVERSITY, such royalties or other payments shall be deposited in local currency in the relevant country to the credit of UNIVERSITY in a recognized banking institution designated by
UNIVERSITY or, if none is designated by UNIVERSITY within a period of [**] days, in a recognized banking institute selected by LICENSEE or its AFFILIATE, or LICENSEE’s or its AFFILIATE’s sublicensees, as the case may be, and identified in
a notice in writing given to UNIVERSITY. 
 3.6 In the event royalty payments or other fees are not received by UNIVERSITY when
due, LICENSEE shall pay to UNIVERSITY interest and charges at a rate of [**]% per month, but in no event in excess of the maximum rate of interest allowed by law on the total royalties or fees due. 

3.7 In the event of default in payment of any payment owing to UNIVERSITY under the terms of this LICENSE AGREEMENT, and if it becomes
necessary for UNIVERSITY to undertake legal action to collect said payment, LICENSEE shall pay all reasonable legal fees and costs incurred by UNIVERSITY in connection therewith. 

ARTICLE 4: REPORTS 
 4.1 LICENSEE agrees to make yearly written summary reports to UNIVERSITY by each [**] summarizing in each such report the then current status of the following, to the extent applicable: 

a) Development and commercialization of LICENSED PRODUCTS and COMPANY PRODUCTS 

b) Collaborations with third parties and sublicensing efforts 
 c) Progress toward completing milestones described in Section 3.4 above 
 d)
Staffing and management 

  
 8 

 e) Finances 
 f) Scientific and business goals for the next year 
 4.2 Following LICENSEE’s
first sale of LICENSED PRODUCT, LICENSEE agrees to make quarterly written reports to UNIVERSITY within [**] days after the last day of each December, March, June and September during the life of this LICENSE AGREEMENT and as of such dates, stating
in each such report the number, description, and NET SALES of LICENSED PRODUCTS sold or otherwise disposed of during the preceding three calendar months and upon which royalty is payable as provided in Section 3.3 above. The first such report
shall include all such LICENSED PRODUCTS so sold or otherwise disposed of prior to the date of such report. Until LICENSEE has achieved a first commercial sale of a LICENSED PRODUCT, a report shall be submitted by LICENSEE within [**] days after the
last day of each December, March, June and September after the EFFECTIVE DATE of this LICENSE AGREEMENT and will include a written report summarizing LICENSEE’s technical and other efforts made towards such first commercial sale of LICENSED
PRODUCTS under development. 
 4.3 LICENSEE will keep complete, true and accurate books of account and records for the purpose
of showing the derivation of all amounts payable to UNIVERSITY under this LICENSE AGREEMENT. Such books and records will be kept at LICENSEE’s principal place of business for at least [**] years following the end of the calendar quarter to
which they pertain, and will be open at all reasonable times upon reasonable prior notice for inspection by an independent certified public accountant engaged by UNIVERSITY for the purpose of verifying LICENSEE’s royalty statements or
LICENSEE’s compliance in other respects with this LICENSE AGREEMENT. Such representative will be obliged to treat as confidential all information obtained during such inspection. 

4.4 Inspections made under Section 4.3 above shall be at the expense of UNIVERSITY, unless a variation or error in any amount
payable to UNIVERSITY under this LICENSE AGREEMENT exceeding [**] percent ([**]%) of the amount due is discovered in the course of any such inspection, whereupon all reasonable costs relating thereto shall be paid by LICENSEE. 

4.5 LICENSEE will promptly pay to UNIVERSITY the full amount of any underpayment, together with interest thereon as set forth in
Section 3.6. Any overpayments by LICENSEE discovered in the course of any inspection under Section 4.3 shall be credited against future amounts payable by LICENSEE hereunder or, with respect to any portion of any overpayment which remains
uncredited as of the effective date of termination or expiration of this Agreement, shall be refunded to LICENSEE within [**] days following such termination or expiration. 
 4.6 Reports due under this Article 4 shall be subject to the confidentiality obligations of Section 12.1. 
 ARTICLE 5: DUE DILIGENCE 
 5.1 LICENSEE shall secure financing of at least
an aggregate of [**] dollars ($[**]) (“INITIAL FINANCING”) within [**] months after the EFFECTIVE DATE. If LICENSEE does not secure such financing within such [**] month period, UNIVERSITY may terminate this

  
 9 

 
LICENSE AGREEMENT immediately upon written notice to LICENSEE, and such termination shall constitute UNIVERSITY’s sole remedy, and LICENSEE’s sole liability, with respect to
LICENSEE’s failure to secure such financing. 
 5.2 LICENSEE shall use commercially reasonable efforts (either itself or
through AFFILIATES or sublicensees) to meet the following development milestone with respect to a COMPANY PRODUCT or LICENSED PRODUCT: 
  

			
	 Milestone
	  	Date of Completion
	 [**]
	  	[**]

 ARTICLE 6: SUBLICENSING 
 6.1 LICENSEE may sublicense any or all of the rights licensed hereunder, provided that (1) such sublicenses (a) cover rights to discover, develop and/or commercialize one or more COMPANY
PRODUCTS or LICENSED PRODUCTS, and (b) (i) cover patent rights which are owned or licensed by LICENSEE (other than the PATENT RIGHTS), or (ii) are granted as part of a bona fide collaboration, (2) all such sublicenses are
consistent with the requirements set forth in Article 11 and Sections 2.8, 4.2, 4.3, 9.2, 9.3, 9.4, 12.1.1, 12.1.3, 12.4, 12.5 and 12.7 of this LICENSE AGREEMENT, (3) all such sublicenses contain the sublicensee’s acknowledgment of the
disclaimer of warranty and limitation on UNIVERSITY’s liability, as provided by Article 10 below, and (4) LICENSEE notifies UNIVERSITY in writing and provides UNIVERSITY with a copy of each such sublicense agreement and each amendment
thereto within [**] days after their execution. LICENSEE shall only grant sublicenses that comport with the above requirements. 

6.2 With respect to sublicenses granted by LICENSEE under this Article 6, LICENSEE’s royalty obligations on NET SALES of LICENSED
PRODUCTS made by sublicensees shall be as set forth in Section 3.3 above, and LICENSEE’s milestone payment obligations on COMPANY PRODUCTS or LICENSED PRODUCTS shall be as set forth in Section 3.4 (a)-(e) above. 

6.3 Notwithstanding the execution of any sublicense agreement, LICENSEE agrees to remain primarily liable to UNIVERSITY for performance
of all of LICENSEE’s duties and obligations contained in this LICENSE AGREEMENT. 
 6.4 Upon termination of this LICENSE
AGREEMENT for any reason, all sublicense agreements shall survive such termination and remain in force and effect in accordance with their terms and shall be assigned to, and assumed by UNIVERSITY, provided, that the sublicensee is in material
compliance with the terms and conditions of its sublicense. LICENSEE shall cause every sublicense agreement to provide LICENSEE the right to assign its rights under the sublicense to UNIVERSITY in the event that this LICENSE AGREEMENT terminates.
For such assignment to be effective, UNIVERSITY must accept such assignment in writing, such written acceptance by UNIVERSITY not to be unreasonably withheld, conditioned or delayed, it being understood that each sublicense agreement that survives
termination hereunder shall 

  
 10 

 
survive even if its assignment to UNIVERSITY is not accepted by UNIVERSITY. Upon LICENSEE’s request, UNIVERSITY shall enter into a “stand-by” license agreement directly with the
applicable sublicensee on customary terms. 
 ARTICLE 7: TERM AND TERMINATION 

7.1 This LICENSE AGREEMENT, including the licenses granted pursuant to Sections 2.1, 2.2 and 2.3, shall begin on the EFFECTIVE DATE and,
unless terminated sooner as herein provided, end at the expiration of the last to expire VALID CLAIM included in the PATENT RIGHTS. Upon expiration of this LICENSE AGREEMENT under this Section 7.1, the licenses granted pursuant to Sections 2.1,
2.2 and 2.3 shall become a fully paid-up, non-royalty-bearing, perpetual license. 
 7.2 UNIVERSITY may, by written notice to
LICENSEE, immediately terminate this LICENSE AGREEMENT in the event that LICENSEE has not met its obligations under Article 5.1, and such termination shall constitute UNIVERSITY’s sole remedy, and LICENSEE’s sole liability, with respect to
LICENSEE’s failure to meet such obligations. Notwithstanding any other provision of any other paragraph of this LICENSE AGREEMENT, LICENSEE shall be given no remedy for this Article 7.2. 

7.3 It is expressly agreed that, notwithstanding the provisions of any other paragraph of this LICENSE AGREEMENT, except as provided in
Article 7.2 above, if LICENSEE should materially breach this LICENSE AGREEMENT and fail to cure any such breach within [**] days of receipt of written notice from UNIVERSITY describing such breach or, if such breach is not susceptible to cure within
[**] days, fail to initiate a cure within such period and diligently pursue a cure until such breach is actually cured, then UNIVERSITY may terminate this LICENSE AGREEMENT upon written notice thereof, such termination to become effective at the end
of the applicable cure period. 
 7.4 If LICENSEE files a petition for or is the subject of a petition for bankruptcy, or is
placed in the hands of a receiver, assignee, or trustee for the benefit of creditors, whether by the voluntary act of LICENSEE or otherwise, and LICENSEE is unable, within one hundred twenty (120) days following any of the events enumerated
above, to secure dismissal, stay or other suspension of such proceedings, then this LICENSE AGREEMENT shall automatically terminate, inasmuch as permitted under applicable and prevailing law. 

7.5 LICENSEE may terminate this LICENSE AGREEMENT at any time upon giving written notice of not less than sixty (60) days to
UNIVERSITY. 
 7.6 Upon termination of this LICENSE AGREEMENT in whole or in part, LICENSEE shall provide UNIVERSITY with a
written inventory of all UNIVERSITY TECHNOLOGY, BIOLOGICAL MATERIALS and LICENSED PRODUCTS in the process of manufacture, in use or in stock as of the effective date of such termination. Except with respect to termination pursuant to
Section 7.3, LICENSEE and its AFFILIATES and sublicensees shall have the privilege of disposing of the inventory of such LICENSED PRODUCTS within a period of [**] days of such termination, subject to LICENSEE’s payment of any royalties
applicable to the sale of such LICENSED PRODUCTS hereunder. LICENSEE and its AFFILIATES and sublicensees will also have the right to complete performance of all contracts for the sale of 

  
 11 

 
LICENSED PRODUCTS by LICENSEE requiring use of UNIVERSITY TECHNOLOGY or PATENT RIGHTS (except in the case of termination pursuant to Section 7.3) within and beyond said period of [**] days
provided that, unless otherwise agreed by the parties, the remaining term of any such contract does not exceed one year. Nothing in this Section 7.6 shall be construed to limit the provisions of Section 6.4. 

7.7 Any termination or expiration under any provision of this LICENSE AGREEMENT shall not relieve either party of its obligation which
have accrued as of the effective date of such termination or expiration, including the obligation of LICENSEE to pay any royalty or other fees due or owing at the time of such termination or expiration. 

ARTICLE 8: PATENT PROSECUTION AND MAINTENANCE 
 8.1 LICENSEE shall bear the cost of all reasonable out-of-pocket patent expenses incurred following the EFFECTIVE DATE associated with the preparation, filing, prosecuting, issuance and maintenance of all
Patent applications and Patents included within the PATENT RIGHTS, except for patent costs associated with PATENT RIGHTS covering INVENTIONS in UNIVERSITY files [**], in which case LICENSEE shall be responsible for only [**] percent ([**])% of the
reasonable out-of-pocket patent expenses associated with the preparation, filing, prosecuting, issuance and maintenance of patent applications and patents included within such PATENT RIGHTS covering INVENTIONS in UNIVERSITY files [**].
Notwithstanding the foregoing, in the event that the non-exclusive license granted to NOVARTIS to practice the PATENT RIGHTS covering INVENTIONS in UNIVERSITY files [**] terminates, LICENSE shall be responsible for 100% of such reasonable
out-of-pocket patent expenses incurred following the EFFECTIVE DATE associated with such PATENT RIGHTS. 
 Such filings and
prosecution shall be by counsel of UNIVERSITY’s choosing and reasonably acceptable to LICENSEE, and shall be in the name of UNIVERSITY. Subject to the remainder of this Article 8, UNIVERSITY shall be responsible for prosecuting and maintaining
the PATENT RIGHTS and shall keep LICENSEE advised as to the prosecution and maintenance of such PATENT RIGHTS by forwarding to LICENSEE (and instructing its patent counsel to forward) copies of all official correspondence (including, but not limited
to, Applications, Office Actions, responses, notification of fees due, etc.) relating thereto. UNIVERSITY shall provide (itself or through such patent counsel) to LICENSEE a copy of each proposed correspondence, including without limitation patent
applications, reasonably in advance of any applicable filing or response deadline to allow LICENSEE to review and comment on the content of such proposed correspondence and advise UNIVERSITY as to the conduct of such prosecution and maintenance, and
UNIVERSITY shall give due consideration to all such comments and advice, provided, however, that UNIVERSITY shall have the right to make the final decisions for all matters associated with such prosecution and maintenance. 

8.2 As regards prosecution and maintenance of foreign patent applications corresponding to any U.S. Patent applications within the PATENT
RIGHTS, LICENSEE shall designate in writing that country or those countries, if any, in which LICENSEE desires such corresponding patent application(s) to be filed. LICENSEE shall pay all costs and legal fees as set forth in Section 8.1
associated with the preparation, filing, prosecuting, issuance and maintenance of such designated foreign patent applications and foreign patents. All such applications shall be in the UNIVERSITY’s name. 

  
 12 

 8.3 By written notification to UNIVERSITY at least [**] days in advance of any filing or
response deadline, or fee due date, LICENSEE may elect not to have a patent application filed in any particular country or not to pay expenses associated with prosecuting or maintaining any patent application or patent, provided that LICENSEE pays
for all costs, as set forth in Section 8.1, incurred up to UNIVERSITY’s receipt of such notification. Failure by LICENSEE to provide such notification within such [**] day period may be deemed by UNIVERSITY as LICENSEE’s notice that
it wishes to support such patent(s) or patent application(s). LICENSEE shall also have the right, at any time and without penalty, to forfeit its rights under this LICENSE AGREEMENT to any PATENT RIGHT upon written notice to UNIVERSITY, provided
that LICENSEE pays for all costs, as set forth in Section 8.1, incurred up to UNIVERSITY’s receipt of such notification and, if there are no remaining PATENT RIGHTS covered under the license granted to LICENSEE hereunder, either party may
terminate this LICENSE AGREEMENT immediately upon written notice to the other party. Upon receipt of any such notice, UNIVERSITY may file, prosecute, and/or maintain such patent applications or patents at its own expense and for its own benefit, and
any rights or license granted hereunder held by LICENSEE, AFFILIATE or SUBLICENSEE(S) relating to such patent application or patent shall terminate. 
 8.4 UNIVERSITY may elect to file corresponding patent applications in countries other than those designated by LICENSEE under Section 8.2, but in that event UNIVERSITY shall so notify LICENSEE and if
LICENSEE notifies UNIVERSITY that it does not desire patent protection in such country, such patent application shall not be deemed a LICENSE PATENT RIGHT hereunder and UNIVERSITY shall be responsible for all costs associated with such
non-designated filings. In such event, LICENSEE shall forfeit its rights under this LICENSE AGREEMENT in the country(ies) where UNIVERSITY exercises its option to file such corresponding patent applications. 

8.5 Notwithstanding any of the foregoing, if UNIVERSITY decides to abandon or discontinue the prosecution and/or maintenance of any
PATENT RIGHTS (upon which decision UNIVERSITY shall give LICENSEE timely advance written notice in a manner that is consistent with UNIVERSITY’s standard practices and, if reasonably possible, provide at least [**] months in advance of the
effective date of UNIVERSITY’s decision), or if UNIVERSITY fails to prosecute and maintain such PATENT RIGHT within a reasonable period of time, LICENSEE shall have the right, but not the obligation, to continue the prosecution and maintenance
of such abandoned PATENT RIGHT, at its sole discretion and expense. 
 ARTICLE 9: INFRINGEMENT 

9.1 If the production, sale or use of LICENSED PRODUCTS under this LICENSE AGREEMENT by LICENSEE results in any third party claim for
patent infringement against LICENSEE, LICENSEE shall promptly notify the UNIVERSITY thereof in writing, setting forth the facts of such claim in reasonable detail. LICENSEE shall have the sole right, in its discretion and at its own expense, to
defend and control the defense and settlement of any such claim against LICENSEE, by counsel of its own choice. UNIVERSITY agrees to cooperate with LICENSEE in any reasonable manner deemed by LICENSEE to be necessary in defending any such action.
LICENSEE shall reimburse UNIVERSITY for any reasonable out of pocket expenses incurred in providing such assistance. 

  
 13 

 9.2 In the event that any PATENT RIGHTS licensed to LICENSEE are infringed by a third party,
LICENSEE shall have the first right, but not the obligation, to institute, prosecute and control (including as to the settlement thereof) any action or proceeding with respect to such infringement, by counsel of its choice, including any declaratory
judgment action arising from such infringement. UNIVERSITY agrees to cooperate with LICENSEE in any reasonable manner deemed by LICENSEE to be necessary in instituting any such action, including the UNIVERSITY joining any such action as a party if
applicable law or court rules provide that a court would lack jurisdiction based on UNIVERSITY’s absence as a party in such action. It is understood that any settlement, consent judgment or other voluntary disposition of such actions that would
materially adversely affect the PATENT RIGHTS must be approved by UNIVERSITY, such approval not to be unreasonably withheld, conditioned or delayed. If LICENSEE recovers monetary damages in the form of lost profits from a third party infringer, then
LICENSEE shall pay to UNIVERSITY the owed royalties on the recovered profits. If LICENSEE recovers monetary damages in the form of a reasonable royalty, then LICENSEE shall remit to UNIVERSITY [**] percent ([**]%) of the reasonable royalty awarded.

 9.3 If LICENSEE elects not to enforce any patent within the PATENT RIGHTS, then LICENSEE shall notify UNIVERSITY in writing
within [**] days of receiving notice that an infringement exists. UNIVERSITY may then, at its own expense and control, take steps to defend or enforce any patent within the PATENT RIGHTS and recover, for its own account, any damages, awards or
settlements resulting therefrom, provided, that UNIVERSITY shall first reimburse LICENSEE for any reasonable expenses and attorneys’ fees incurred by LICENSEE relating to the suit. 

9.4 Notwithstanding the foregoing, and in UNIVERSITY’s sole discretion and expense, UNIVERSITY shall be entitled to participate
through counsel of its own choosing in any legal action involving the INVENTION and PATENT RIGHTS. Nothing in the foregoing sections shall be construed in any way which would limit the authority of the Attorney General of North Carolina. 

ARTICLE 10: REPRESENTATIONS 
 10.1 UNIVERSITY makes no warranties that any patent will issue on UNIVERSITY TECHNOLOGY or INVENTION. UNIVERSITY does not warrant the validity of any patent included in the PATENT RIGHTS or that practice
under such patents shall be free of infringement. 
 10.2 UNIVERSITY represents and warrants that (a) it has the authority
to execute and deliver this LICENSE AGREEMENT, (b) to the best of its knowledge, after reasonable inquiry, it owns all right, title and interest in and to the PATENT RIGHTS, UNIVERSITY TECHNOLOGY and BIOLOGICAL MATERIALS, (c) to the best
of its knowledge, after reasonable inquiry, it has the right to grant the licenses granted to LICENSEE on the terms set forth herein and to perform the other transactions contemplated under the LICENSE AGREEMENT without violating any agreement,
instrument or contractual obligation to which UNIVERSITY is bound (which representation does not limit the representation set forth in clause (d)), (d) as of the EFFECTIVE DATE, UNIVERSITY has granted solely to NOVARTIS, and to no other person
or entity, a non-exclusive license to practice BIOLOGICAL 

  
 14 

 
MATERIALS, and PATENT RIGHTS covering INVENTIONS, described in UNIVERSITY files [**], and the terms of this LICENSE AGREEMENT do not conflict with the terms of UNIVERSITY’s license agreement
with NOVARTIS, (e) the patent costs incurred by UNIVERSITY with respect to PATENT RIGHTS as of the EFFECTIVE DATE are $[**] and no more, and (f) to the best of its knowledge, after reasonable inquiry, each patent and patent application
included within the PATENT RIGHTS as of the EFFECTIVE DATE sets forth a complete and accurate list of inventors. 
 10.3 EXCEPT
AS EXPRESSLY SET FORTH HEREIN, UNIVERSITY DISCLAIMS ALL WARRANTIES WITH REGARD TO PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESSED OR IMPLIED, OF MERCHANTABILITY AND FITNESS FOR ANY
PARTICULAR PURPOSE. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY AND INVENTORS, FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT,
SPECIAL, AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE
OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. LICENSEE, AFFILIATE(S) AND SUBLICENSEE(S) ASSUME ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT AND/OR SERVICE MANUFACTURED, USED, OR SOLD BY LICENSEE, ITS
SUBLICENSEE(S) AND AFFILIATE(S) WHICH IS A LICENSED PRODUCT(S) AS DEFINED IN THIS AGREEMENT. 
 ARTICLE 11: INDEMNIFICATION

 11.1 In exercising its rights under this LICENSE AGREEMENT, LICENSEE shall use commercially reasonable efforts to comply
in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this LICENSE AGREEMENT. LICENSEE further agrees to indemnify
and hold UNIVERSITY harmless from and against any costs, expenses, attorney’s fees, citation, fine, penalty and liability of every kind and nature which might be imposed on UNIVERSITY by reason of any asserted or established violation by
LICENSEE of any such laws, order, rules and/or regulations. 
 11.2 LICENSEE agrees to indemnify, hold harmless and defend
UNIVERSITY, its officers, employees, and agents (collectively, “UNIVERSITY INDEMNITEES”), against any and all claims, suits, losses, damage, costs, fees, and expenses asserted by third parties, both government and private, (including
without limitation reasonable attorneys’ fees and other reasonable costs and expenses of defense) (collectively, “CLAIMS”) resulting from or arising out of the exercise of this LICENSE AGREEMENT. The previous sentence shall not apply
to any CLAIM that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of, or the breach of this LICENSE AGREEMENT by, any UNIVERSITY INDEMNITEE. 

  
 15 

 11.3 HHMI, and its trustees, officers, employees, and agents (collectively, “HHMI
INDEMNITEES”), will be indemnified, defended by counsel acceptable to HHMI (which acceptance shall not be unreasonably withheld, conditioned or delayed), and held harmless by the LICENSEE, from and against any CLAIM based upon, arising out of,
or otherwise relating to this LICENSE AGREEMENT, sublicense, or other contract or agreement, including without limitation any cause of action relating to product liability. The previous sentence will not apply to any CLAIM that is determined with
finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI INDEMNITEE. 
 11.4 With respect to any CLAIM for which an UNIVERSITY INDEMNITEE or HHMI INDEMNITEE seeks indemnification under Section 11.1, 11.2 or 11.3, as applicable, UNIVERSITY shall promptly notify LICENSEE
of such CLAIM. In the case of any HHMI INDEMNITEE, notice shall be given reasonably promptly following actual receipt of written notice thereof by an officer or attorney of HHMI. Notwithstanding the foregoing, the delay or failure of any HHMI
INDEMNITEE to give reasonably prompt notice to LICENSEE of any such claim shall not affect the rights of such HHMI INDEMNITEE unless, and then only to the extent that, such delay or failure is prejudicial to or otherwise adversely affects LICENSEE.
LICENSEE shall manage and control, at its sole expense, the defense of the CLAIM and its settlement, provided, that, LICENSEE shall not enter into any settlement of such CLAIM that would impose any liability or obligation on any UNIVERSITY
INDEMNITEE without such UNIVERSITY INDEMNITEE’s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed). In addition, LICENSEE agrees not to settle any CLAIM against an HHMI INDEMNITEE without
HHMI’s written consent , where (a) such settlement would include any admission of liability on the part of any HHMI Indemnitee, (b) such settlement would impose any restriction on any HHMI INDEMNITEE’s conduct of any of its
activities, or (c) such settlement would not include an unconditional release of all HHMI INDEMNITEES from all liability for claims that are the subject matter of the settled CLAIM. Any UNIVERSITY INDEMNITEE or HHMI INDEMNITEE being indemnified
hereunder shall cooperate with LICENSEE in LICENSEE’s defense and settlement of such CLAIM. 
 11.5 LICENSEE is required to
maintain (itself or through its AFFILIATES or sublicensees) in force at its sole cost and expense, with reputable insurance companies, general liability insurance and products liability insurance coverage in an amount reasonably sufficient to
protect against liability under Sections 11.1, 11.2, and 11.3 above, taking into account the nature and size of LICENSEE’s business to which this LICENSE AGREEMENT relates and the stage of development of products under this LICENSE AGREEMENT,
and subject to normal deductions and limits. Notwithstanding the foregoing, LICENSEE may satisfy its obligations hereunder through the maintenance of a reasonable self-insurance program by a large pharmaceutical company (i.e., with at least $[**] in
sales in its most recent year) as a sublicensee hereunder. The UNIVERSITY shall have the right to ascertain from time to time that such coverage exists, such right to be exercised in a reasonable manner. 

ARTICLE 12: MISCELLANEOUS 
 12.1 Confidentiality.  
 12.1.1 LICENSEE shall keep confidential
and, without prior written consent of UNIVERSITY, shall not disclose any UNIVERSITY TECHNOLOGY or any patent applications 

  
 16 

 
furnished by UNIVERSITY pursuant to this LICENSE AGREEMENT to third parties, except (a) to existing and prospective investors, lenders, acquirors, collaborators, licensees and other parties
in the chain of development, manufacturing, commercialization and distribution, in each case under a confidentiality agreement with terms no less restrictive than those contained in this Section 12.1, or (b) to the extent necessary to
obtain regulatory approval for, or to sell, a LICENSED PRODUCT or COMPANY PRODUCT, or to obtain patent protection in connection with such LICENSED PRODUCT or COMPANY PRODUCT. 
 12.1.2. In consideration of the disclosure of CONFIDENTIAL INFORMATION by LICENSEE during the term of this LICENSE AGREEMENT, including in the form of reports as required in Article 4 and copies of
sublicense agreements pursuant to Section 6.1 above, UNIVERSITY hereby agrees that it will: 
  

	 	(a)	keep such information secret and confidential, and not at any time without the prior written consent of LICENSEE disclose or reveal such reports to any third party or
use such information other than for purposes of performing this LICENSE AGREEMENT; and 

  

	 	(b)	treat such information with the same degree of care as it treats its own confidential information, but no less than reasonable care. 

12.1.3 The undertakings of confidentiality in Sections 12.1.1 and 12.1.2 above shall not apply to any information which the recipient can
prove by written evidence: (i) is in or comes into the public domain or ceases to be confidential, other than as a result of wrongful disclosure by recipient; (ii) becomes available to recipient on a non-confidential basis from a third
party source under no duty of confidentiality to provider; (iii) is independently generated by recipient employees without reference to such information; or (iv) is required to be disclosed by any applicable law or order of a court of
competent jurisdiction, or by the rules, regulations, requirements or order of any recognized stock exchange or other regulatory or governmental authority, provided always that prior to making such disclosure recipient shall (to the extent
practicable or permitted by law) consult with provider as to the proposed form, nature, extent and purpose of the disclosure and shall use commercially reasonable efforts to ensure that any such disclosure is kept to a minimum and to permit
recipient sufficient time to apply for and obtain a protective order against such disclosure. 
 12.2 Assignability. This
LICENSE AGREEMENT is binding upon and shall inure to the benefit of the UNIVERSITY, LICENSEE, and each party’s successors and assigns. However, this LICENSE AGREEMENT shall be personal to LICENSEE, and it is not assignable by LICENSEE to any
other person or entity without the written consent of UNIVERSITY, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, LICENSEE shall be free to assign this LICENSE AGREEMENT in connection with any
merger or sale of all or substantially all of its assets or business to which this LICENSE AGREEMENT relates without the consent of the UNIVERSITY. 
 12.3 Waiver. It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent
and/or similar breach or default. 

  
 17 

 12.4 Use of UNIVERSITY’s Name. The use of the name of UNIVERSITY, or any
contraction thereof, in any manner in connection with the exercise of this LICENSE AGREEMENT is expressly prohibited without the prior written consent of UNIVERSITY, except as otherwise may be required by applicable law, or any judicial,
governmental, regulatory or stock exchange requirement, regulation, rule or order. 
 12.5 HHMI as Third Party
Beneficiary. HHMI is not a party to this LICENSE AGREEMENT and has no liability to any licensee, sublicensee, or user of anything covered by this License Agreement, but HHMI is an intended third-party beneficiary of the provisions of this
LICENSE AGREEMENT that are expressly stated as being for the benefit of HHMI, which provisions are enforceable by HHMI in its own name. 
 12.6 Independent Contractor Status. Neither party hereto is an agent of the other for any purpose. 
 12.7 U.S. Manufacture. It is agreed, as required by 35 U.S.C. § 204, that any LICENSED PRODUCTS used or sold in the United States shall be substantially manufactured in the United
States. 
 12.8 Notice. Any notice required or permitted to be given to the parties hereto shall be in writing and deemed
to have been properly given (a) upon delivery, if delivered in person, (b) on the next business day if delivered by reputable overnight courier, or (c) three (3) business days after the date mailed if mailed by first-class mail,
return receipt requested, in each case to the other party at the appropriate address as set forth below. Other addresses may be designated in writing by the parties during the term of this LICENSE AGREEMENT. 

 

							
		 	UNIVERSITY	 	LICENSEE	 	
				
		 	Catherine Innes	 	Epizyme, Inc.	 	
		 	Director	 	c/o MPM Capital L.P.	 	
		 	Office of Technology Development	 	The John Hancock Tower	 	
		 	CB #4105, 308 Bynum Hall	 	200 Clarendon Street	 	
		 	UNC-CH	 	54th Floor	 	
		 	Chapel Hill, NC 27599-4105	 	Boston, MA 02116	 	
		 		 	Attn: Kazumi Shiosaki	 	
				
		 		 	With a copy to:	 	
				
		 		 	WilmerHale LLP	 	
		 		 	60 State Street	 	
		 		 	Boston, MA 02109	 	
		 		 	Attn: David E. Redlick, Esq.	 	

 12.9 Governing Law. This LICENSE AGREEMENT shall be interpreted and construed in accordance with
the laws of the State of North Carolina. 
 12.10 Dispute Resolution. If a dispute arises out of or relates to this
LICENSE AGREEMENT or its breach, the parties shall try to amicably resolve such dispute through 

  
 18 

 
negotiation. If the dispute cannot be settled through negotiation within [**] days, UNIVERSITY and LICENSEE agree to submit the dispute for resolution through arbitration conducted in accordance
with the commercial arbitration rules of the American Arbitration Association by a single arbitrator appointed in accordance with such rules. The demand for arbitration shall be filed within a reasonable time after the controversy or claim has
arisen, and in no event after the date upon which institution of legal proceedings based on such controversy or claim would be barred by the applicable statute of limitation. Such arbitration shall be held in Washington, D.C. The award through
arbitration shall be final and binding on the parties. Either party may enter any such award with a court having jurisdiction or may make application to such court for judicial acceptance of the award and an order of enforcement, as the case may be.
Notwithstanding the foregoing, either party hereto shall have the right, without waiving any right or remedy available to such party under this LICENSE AGREEMENT, to seek and obtain from any court of competent jurisdiction any interim or provisional
relief that is necessary or desirable to protect the rights or property of such party, pending the selection of the arbitrator hereunder or pending the arbitrator’s determination of any dispute, controversy or claim hereunder. In addition,
notwithstanding the foregoing, no dispute affecting the rights or property of HHMI shall be subject to the arbitration provisions set forth above. 
 12.11 Complete Agreement. It is understood and agreed between UNIVERSITY and LICENSEE that this LICENSE AGREEMENT (including all exhibits hereto) and the STOCK PURCHASE AGREEMENT (as defined in
Section 3.2.2) constitute the entire agreement, both written and oral, between the parties, as to the subject matter hereof, and that all prior agreements respecting the subject matter hereof, either written or oral, expressed or implied, are
null and void and of no further force or effect. 
 12.12 Severability. In the event that any provision of this
LICENSE AGREEMENT is found to be invalid or unenforceable, such finding shall have no effect on the remaining provisions of this LICENSE AGREEMENT, which shall continue in full force and effect. The parties shall consult and use commercially
reasonable efforts to agree upon a valid and enforceable provision which shall be a reasonable substitute for any provision which is found to be invalid or unenforceable in light of the intent of this LICENSE AGREEMENT. 

12.13 Survival of Terms. The provisions of Sections 2.8, 4.3, 4.4, 4.5, 4.6, 6.4, 7.1 (last sentence only), 7.6 and 7.7, and
Articles 3 (solely to the extent that any amounts are due but unpaid hereunder), 11 and 12, shall survive the expiration or termination of this LICENSE AGREEMENT. 
 12.14 Counterpart Signatures. This LICENSE AGREEMENT may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the
same instrument. 
 [Signature Page to Follow] 

  
 19 

 IN WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this LICENSE AGREEMENT on the
EFFECTIVE DATE, in duplicate originals, by the duly authorized respective officers. ZHANG has likewise indicated his acceptance of the terms hereof by signing below. 
  

					
	THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	  		  	EPIZYME, INC.
			
	 /s/ Catherine Innes
	  		  	 /s/ Kazumi Shiosaki

	Signature	  		  	Signature
			
	 Catherine Innes
	  		  	 Kazumi Shiosaki

	Printed Name	  		  	Printed Name
			
	 Director, Office of Technology Development
	  		  	 President and CEO

	Title	  		  	Title
			
	1/7/08	  		  	January 7 2008
	Date	  		  	Date

 ACKNOWLEDGED AND AGREED BY: 
 ZHANG: 
  

	
	 /s/ Yi Zhang

	Signature
	
	 Yi Zhang, Ph.D.

	Printed Name
	
	1/7/08
	Date

  
 20 

 APPENDIX A – PATENT RIGHTS 
 EZH2 Family (UNIVERSITY file [**]) 
 [**] 

JMJ Demethylase Family (UNIVERSITY files [**]) 
 [**] 
 DOT1 Family (UNIVERSITY files [**]) 

[**] 
 BMI-1 Family (UNIVERSITY file [**])

 [**] 
 [**] 

  
 21 

 APPENDIX A (continued) - BIOLOGICAL MATERIALS 
  
 Reagents transferred: 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of three pages were omitted. [**] 

  
 22 

 APPENDIX B – STOCK PURCHASE AGREEMENT 

  
 23 

 EPIZYME, INC. 
 COMMON STOCK PURCHASE AGREEMENT 
 THIS COMMON STOCK PURCHASE AGREEMENT (the
“Agreement”) is made as of January 22, 2008, by and between Epizyme, Inc., a Delaware corporation (the “Company”), and the University of North Carolina Foundation, Inc., a nonprofit institution organized under
the laws of North Carolina (the “Purchaser”). 
 The parties hereby agree as follows: 

1. Purchase and Sale of Common Stock. 
 1.1 Sale and Issuance of Initial Closing Shares. No later than thirty (30) days after the Effective Date (as defined in the License Agreement (as defined in Section 2 below)), the Company
shall issue to the Purchaser, on the terms and conditions contained in this Agreement, [**] shares (the “Initial Closing Shares”) of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”),
which number of shares represents [**] percent ([**]%) of the total number of issued and outstanding Equity Securities (as defined in the License Agreement) of the Company as of the Effective Date (as defined in the License Agreement). The purchase
and sale of the Initial Closing Shares shall take place on a date designated by the Company (or on such other date as the Company and the Purchaser mutually agree upon), which shall be referred to in this Agreement as the “Initial
Closing.” 
 1.2 Sale and Issuance of Additional Shares. In accordance with and subject to
Section 3.2.1 of the License Agreement, the Company shall from time to time, if necessary, issue to the Purchaser additional shares of Common Stock (the “Additional Shares”) on a pro rata basis, so that the Purchaser’s
ownership of outstanding Common Stock shall not fall below [**] percent ([**]%) of the Company’s issued and outstanding Equity Securities (as defined in the License Agreement), as calculated after giving effect to such issuance of additional
shares. Each purchase and sale of Additional Shares shall take place on a date designated by the Company (or on such other date as the Company and the Purchaser mutually agree upon), each of which shall be referred to in this Agreement as an
“Additional Closing.” 
 1.3 Trigger Financing. In accordance with Section 3.2.1 of
the License Agreement, no Additional Closings shall occur and no Additional Shares shall be issued to the Purchaser under the Agreement after the Trigger Financing (as defined in the License Agreement) has occurred. 

1.4 Definitions. The Initial Closing Shares and any Additional Shares issued to the Purchaser under this Agreement
are collectively referred to in this Agreement as the “Shares.” The Initial Closing and any Additional Closings are collectively referred to herein as the “Closings.” In this Agreement, the term
“Closing” shall apply to each of the Initial Closing and any Additional Closing unless otherwise specified. 

  
 24 

 1.5 Stock Certificates. At each Closing, the Company shall deliver to
the Purchaser one or more stock certificate(s) representing the Shares being issued to the Purchaser at such Closing. 
 2.
Consideration; Expiration or Termination of License Agreement. The Shares issued at each Closing are being issued as partial consideration for The University of North Carolina at Chapel Hill (the “University”) entering into
and performing its obligations under that certain License Agreement dated January 7, 2008 by and between the University and the Company (the “License Agreement”). No cash consideration is payable by the Purchaser for the
purchase of the Shares. Notwithstanding anything to the contrary in this Agreement, from and after the termination or expiration of the License Agreement, the Company shall not be obligated to issue any additional Shares pursuant to this Agreement.

 3. Representations and Warranties of the Company. The Company hereby represents and warrants to the Purchaser that as
of the date of this Agreement: 
 3.1 The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as presently conducted and as proposed to be conducted. 

3.2 The Shares, when issued, sold and delivered in accordance with the terms set forth in this Agreement, will be validly
issued, fully paid and nonassessable. 
 3.3 The Company’s Certificate of Incorporation and Bylaws in effect
immediately prior to the Initial Closing are each in the form provided to the Purchaser. 
 3.4 The Company is
not a party to any actions, suits, or proceedings pending or, to the Company’s knowledge, threatened against or affecting the Company, its officers or directors in their capacity as such or its properties in any court or before any governmental
or administrative agency, which would reasonably be expected to have a material adverse effect on the Company’s business as now conducted or as currently proposed to be conducted or on its properties, financial condition, or income, or the
transactions contemplated by this Agreement or the License Agreement, and the Company is not in default under any order or judgment of any court or governmental or administrative agency. 

3.5 The Company is not a party to any agreement or instrument, or subject to any charter, bylaw, or other corporate
restrictions materially adversely affecting its business and operations, or its property, assets, or financial condition. 
 3.6 The Company is not in material default or breach in the performance, observance, or fulfillment of any of the obligations, covenants, or conditions contained in any bond, debenture, note, or other
evidence of indebtedness or any material contract or other agreement of the Company. 
 3.7 This Agreement has
been duly authorized, executed, and delivered on behalf of the Company and constitutes the valid and binding agreement of the Company, enforceable in accordance with its terms, and the Company has full power and lawful authority to issue and sell
the Shares on the terms and conditions herein set forth. 

  
 25 

 3.8 Consummation of the transactions contemplated by this Agreement in
compliance with the provisions of this Agreement will not result in any material breach of any of the terms, conditions, or provisions of, or constitute a material default under, or result in the creation of any lien, charge, or encumbrance on, any
property or assets of the Company pursuant to any indenture, mortgage, deed of trust, agreement, corporate charter, bylaws, contract, or other instrument to which the Company is a party or by which the Company may be bound or any law, rule,
regulation, qualification, license, order or judgment applicable to the Company or any of its property. 
 3.9
The Company is in material compliance with all applicable federal, state and local environmental laws and, to the Company’s knowledge, there are no conditions currently existing or contemplated which are likely to subject the Company to
damages, penalties, injunctive relief, removal costs, remedial costs or cleanup costs under any such laws or assertions thereof. 
 3.10 There are no restrictions relating to the transfer and voting of the Shares issued to the Purchaser hereunder, other than under applicable securities laws and this Agreement. 

3.11 Since its incorporation, the Company has been engaged solely in organizational activities, recruiting employees,
executives and advisors, entering into this Agreement and the License Agreement, raising capital and otherwise commencing operations as a biotechnology company, and has not incurred any extraordinary liabilities beyond those necessary to engage in
the foregoing activities. 
 3.12 The Company has timely filed all tax returns and reports required to be filed
by it. The Company has timely paid all taxes, interest and penalties required to be paid pursuant to said returns or otherwise required to be paid by it. 
 4. Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company that as of the date of this Agreement: 

4.1 The Purchaser is aware of the Company’s business affairs and financial condition and has acquired sufficient
information about the Company to reach an informed and knowledgeable decision to acquire the Shares. The Purchaser is acquiring the Shares for investment for the Purchaser’s own account only and not with a view to, or for resale in connection
with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). 
 4.2 The Purchaser understands that the Shares have not been registered under the Securities Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide
nature of the Purchaser’s investment intent as expressed herein. 
 4.3 The Purchaser further acknowledges
and understands that the Shares must be held indefinitely unless they are subsequently registered under the Securities Act or 

  
 26 

 
an exemption from such registration is available. The Purchaser further acknowledges and understands that the Company is under no obligation to register the Shares. The Purchaser understands that
the certificate evidencing the Shares will be imprinted with a legend in a form satisfactory to the Company which prohibits the transfer of the Shares unless they are registered or such registration is not required in the opinion of counsel to the
Company. 
 4.4 The Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated
under the Securities Act. 
 5. Conditions to Closing. The obligations of the Company to issue Shares at the Initial
Closing or any Additional Closing are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless otherwise waived by the Purchaser in the case of Section 5.1 and by the Company in the case of
Section 5.2: 
 5.1 Representations and Warranties of the Company. The representations and warranties
of the Company contained in Section 3 hereof shall be true and correct in all respects as of such Closing. 

5.2 Representations and Warranties of the Purchaser. The representations and warranties of the Purchaser contained
in Section 4 hereof shall be true and correct in all respects as of such Closing. 
 6. Right of First Refusal.

 6.1 If the Purchaser proposes to transfer any Shares, then the Purchaser shall first give written notice of
the proposed transfer (the “Transfer Notice”) to the Company. The Transfer Notice shall name the proposed transferee and state the number of such Shares that the Purchaser proposes to transfer (the “Offered
Shares”), the price per share and all other material terms and conditions of the transfer. 
 6.2 For
thirty (30) days following delivery to the Company of such Transfer Notice, the Company shall have the option to purchase all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the
Company elects to purchase all or part of the Offered Shares, it shall give written notice of such election to the Purchaser within such thirty (30) day period. Within ten (10) days after delivery to the Purchaser of such notice, the
Purchaser shall tender to the Company at its principal offices the certificate or certificates representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the Purchaser or with duly endorsed stock powers attached
thereto, all in form suitable for transfer of the Offered Shares to the Company. Promptly following receipt of such certificate or certificates, the Company shall deliver or mail to the Purchaser a check in payment of the purchase price for the
Offered Shares; provided that if the terms of payment set forth in the Transfer Notice were other than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice.

 6.3 If the Company does not elect to acquire any of the Offered Shares, the Purchaser may, within the thirty
(30) day period following the expiration of the option granted to the Company under Section 6.2 above, transfer the Offered Shares which the Company has not elected to acquire to the proposed transferee, provided that such transfer

  
 27 

 
shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice. Notwithstanding any of the above, all Offered Shares transferred pursuant to
this Section 6 shall remain subject to this Agreement (including without limitation the right of first refusal set forth in this Section 6) and such transferee shall, as a condition to such transfer, deliver to the Company a written
instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement. 

6.4 After the time at which the Offered Shares are required to be delivered to the Company for transfer to the Company
pursuant to Section 6.2 above, the Company shall not pay any dividend to the Purchaser on account of such Offered Shares or permit the Purchaser to exercise any of the privileges or rights of a stockholder with respect to such Shares, but
shall, in so far as permitted by law, treat the Company as the owner of such Offered Shares. 
 6.5 The following
transactions shall be exempt from the provisions of this Section 6: 
 (a) any transfer pursuant to an effective
registration statement filed by the Company under the Securities Act; and 
 (b) the sale of all or substantially all of the
shares of capital stock of the Company (including pursuant to a merger or consolidation). 
 6.6 The Company may
assign its rights to purchase Offered Shares in any particular transaction under this Section 6 to one or more persons or entities. 
 6.7 The provisions of this Section 6 shall terminate upon the earlier of the following events: 
 (a) the closing of the sale of shares of Common Stock in an underwritten public offering pursuant to an effective registration statement filed by the Company under the Securities Act or such time as the
Company has a class of equity securities registered under the Securities Exchange Act of 1934, as amended; or 
 (b) the sale of
all or substantially all of the capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who were
beneficial owners of the Common Stock immediately prior to such transaction beneficially own, directly or indirectly, more than 60% of the outstanding securities entitled to vote generally in the election of directors of the resulting, surviving or
acquiring corporation in such transaction). 
 6.8 The Company shall not be required (a) to transfer on its
books any of the Shares which shall have been sold or transferred in violation of any of the provisions set forth in this Agreement, or (b) to treat as owner of such Shares or to pay dividends to any transferee to whom any such Shares shall
have been so sold or transferred. 

  
 28 

 7. Stock Certificate Legends. The stock certificate(s) evidencing the Shares issued
hereunder shall be endorsed with the following legends, in addition to any legends that may be required by applicable law: 
 THE SHARES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933. 

THE SHARES OF STOCK REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER AND FORFEITURES AS SET FORTH IN A CERTAIN COMMON STOCK
PURCHASE AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED OWNER OF THESE SHARES (OR ITS PREDECESSOR IN INTEREST), AND SUCH AGREEMENT IS AVAILABLE FOR INSPECTION WITHOUT CHARGE AT THE OFFICE OF THE SECRETARY OF THE COMPANY. 

8. Agreement in Connection with Public Offering. The Purchaser hereby agrees that it will not, without the prior written consent
of the managing underwriter, during the period commencing on the date of the final prospectus relating to the initial underwritten public offering of the Company (the “IPO”) and ending on the date specified by the Company and the
managing underwriter (such period not to exceed l80 days, plus up to an additional 34 days to the extent requested by the managing underwriters for such offering in order to address Rule 2711(f) of the Financial Industry Regulatory Authority, Inc.
or any similar successor provision) (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or
dispose of, directly or indirectly, any securities of the Company held immediately prior to the effectiveness of the registration statement for such offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of other securities, in cash or otherwise. The foregoing
provisions of this Section 8 shall apply only to the IPO and shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement or to shares acquired following the IPO. The underwriters in connection with the IPO
are intended third-party beneficiaries of this Section 8 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. The Purchaser further agrees to execute such agreements as may be
reasonably requested by the underwriters in the IPO that are consistent with this Section 8 or that are reasonably necessary to give further effect thereto. In order to enforce the foregoing covenants, the Company may impose stop-transfer
instructions with respect to the securities of the Company held by the Purchaser (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. 

9. General Provisions. 
 9.1 Governing Law. This Agreement shall be governed by the laws of the State of Delaware without regard to principles relating to conflicts of law. 

9.2 Notice. Any notice, demand or request required or permitted to be given by either the Company or a Purchaser
pursuant to the terms of this Agreement shall be in writing and shall be deemed given when delivered personally or deposited in the United 

  
 29 

 
States mail, first class with postage prepaid, and addressed to the party at the address of the party set forth at the end of this Agreement or such other address as a party may request by
notifying the other in writing. 
 9.3 Assignability. The rights and benefits of the Company under this
Agreement shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company’s successors and assigns. The rights and obligations of the
Purchaser under this Agreement may only be assigned with the prior written consent of the Company and any purported transfer otherwise shall be null and void. 
 9.4 Waiver. Any party’s failure to enforce any provision or provisions of this Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent that
party thereafter from enforcing each and every other provision of this Agreement. The rights granted to the parties herein are cumulative and shall not constitute a waiver of any party’s right to assert all other legal remedies available to it
under the circumstances. 
 9.5 Amendments. Any term of this Agreement may be amended, terminated or
waived only with the written consent of each of the parties hereto. 
 9.6 Counterparts. This Agreement
may be executed in counterparts and signatures may be delivered via facsimile, each of which may be executed by less than all parties, each of which shall be enforceable against the parties actually executing such counterparts, and all of which
together shall constitute one instrument. 
 9.7 Titles. The titles used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this Agreement. 
 9.8
Severability. If one more provisions of this Agreement are held to be unenforceable, such provision(s) shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision we so excluded and shall
be enforceable in accordance with its terms. 
 9.9 Entire Agreement. This Agreement and the License
Agreement constitute the entire agreement between the parties hereto pertaining to the subject matter hereof; provided, however, that in the event of any inconsistency between the terms of this Agreement and the License Agreement, the terms of this
Agreement shall govern. Any and all other written or oral agreements existing between the parties hereto are expressly cancelled. 
 [SIGNATURE PAGE FOLLOWS] 

  
 30 

 Execution Version 

IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above. 

 

			
	COMPANY:
	
	EPIZYME, INC.
		
	By:	 	 /s/ Kazumi Shiosaki

		 	Name:     Kazumi Shiosaki
		 	Title:       CEO
		 	Address:    c/o MPM Capital
		 	200 Clarendon St., #54
		 	Boston, MA 02116

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the
date first written above. 
  

					
	PURCHASER:
	
	UNIVERSITY OF NORTH CAROLINA FOUNDATION, INC.
		
	By:	 	 /s/ Richard L. Mann

		 	Name:	 	Richard L. Mann
		 	Title:	 	Treasurer
		 	Address:	 	

  
 32EX-10.22

 Exhibit 10.22 
 Confidential Materials omitted and filed separately with the 
 Securities and
Exchange Commission. Double asterisks denote omissions. 
 Execution Document 2/27/13 

DEVELOPMENT AND COMMERCIALIZATION AGREEMENT 

THIS DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this
“Agreement”) is effective as of February 28, 2013 (“Effective Date”), by and between Abbott Molecular Inc., a corporation organized under the laws of Delaware (“Abbott”), and Epizyme, Inc.
(“Epizyme”), a corporation organized under the laws of Delaware. 
 RECITALS 

A. Epizyme is developing a certain proprietary compound, a DOT1L inhibitor known as EPZ-5676, for the treatment of acute leukemias that
result from MLL translocations. 
 B. Abbott is in the business of developing and marketing in vitro diagnostic devices and has
developed certain technology and possesses experience relating to the preparation and development of FISH assays performed on specimens. 
 C. Epizyme desires that a fluorescence in situ hybridization diagnostic test to detect MLL translocations (“Diagnostic Test,” as further defined herein) be developed, registered and
commercialized in conjunction with Epizyme’s registration, marketing and sale of an Epizyme Product (as further defined below), and Abbott is willing to undertake such activities pursuant to the provisions of this Agreement. 

NOW, THEREFORE, in consideration of these premises and the terms and conditions contained herein, the
Parties hereto agree as follows. 
 ARTICLE 1 

DEFINITIONS 
 As used in this Agreement, the following terms shall have the following meanings, whether used in the singular or plural: 
 “Abbott” shall have the meaning set forth in the Preamble. 
 “Abbott
Claim” shall have the meaning set forth in Section 10.1(a). 
 “Abbott Diagnostics” shall mean any and all
existing FISH assay platforms/systems (including the VP 2000TM and ThermoBriteTM) and FISH assay reagents, kits and protocols for use on existing FISH assay platforms/systems developed, Controlled, or sold by Abbott, and all related
development, manufacturing and commercialization activities, including the Diagnostic Test. 
 “Abbott Inventions” shall have
the meaning set forth in Section 7.8(b). 
 “Abbott Losses” shall have the meaning set forth in Section 10.1(a).

 “Abbott Know-How” means all Know-How relating to or arising from the Abbott Diagnostics
which is (i) existing now or at any time in the future, and (ii) Controlled by Abbott independent of this Agreement, and (iii) necessary for the development or commercialization of the Diagnostic Test. 

“Abbott Party” shall have the meaning set forth in Section 10.1(a). 
 “Abbott Patent Rights” means all Patent Rights (a) covering Abbott’s FISH Platform Technology or (b) covering the Diagnostic Test, which are Controlled now or at any time
in the future by Abbott or its Affiliates independent of this Agreement. 
 “Abbott Technology” shall mean, collectively,
Abbott Patent Rights and Abbott Know-How, to the extent such Abbott Know-How specifically relates to Abbott Diagnostics or the Diagnostic Test. 

“Affiliate” shall mean any Person which controls, is controlled by, or is under common control with the applicable Person. For purposes
of this definition, “control” shall mean: (a) in the case of corporate entities, direct or indirect ownership of fifty percent (50%) or more of the stock or shares (or such lesser percentage which is the maximum allowed to be
owned by a foreign corporation in a particular jurisdiction) entitled to vote for the election of directors, or otherwise having the power to control or direct the affairs of such Person; and (b) in the case of non-corporate entities, direct or
indirect ownership of at least 50% of the equity interest or the power to direct the management and policies of such noncorporate entities. 

“Agreement” shall have the meaning set forth in the Preamble. 
 “Alliance Lead” shall have the meaning set forth in Section 4.7. 

“Applicable Law” shall mean all applicable provisions of all statutes, laws, rules, regulations, administrative codes, ordinances,
decrees, orders, decisions, injunctions, awards judgments, permits and licenses of or from governmental authorities, including those relating to or governing the use or regulation of the subject item and the listing standards or agreements of any
national or international securities exchange. 
 “Breaching Party” shall have the meaning set forth in Section 9.2.

 “Bridging and Clinical Trial Site Costs” shall include the costs incurred by Abbott in accordance with the budget estimate
set forth in Exhibit E in performing clinical studies; validation studies; laboratory start-up costs; investigational review board costs; case report forms; shipping cost for supplies and slides; monitoring visits (including travel costs);
and reagents and other consumable products, all as necessary in connection with conducting clinical trials to obtain required Regulatory Approvals for the Diagnostic Test for the Diagnostic Test Intended Use. Abbott shall not exceed the budget
estimate for such costs set forth in Exhibit E unless the excess costs have been approved in advance by Epizyme. 
 “CDA” shall
mean that Disclosure Agreement executed by the Parties as of January 11, 2012. 

  
 2 

 “Claim” shall have the meaning set forth in Section 10.3(a). 

“Commercially Reasonable Efforts” shall mean, with respect to the research, development and sale of any Epizyme Product by Epizyme, or
of the Diagnostic Test by Abbott, such efforts and resources substantially equivalent to those efforts and resources commonly used by Abbott for diagnostic products and by Epizyme for pharmaceutical products, in each case as such product is owned by
such Party or to which such Party has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved labeling, the competitiveness of alternative Third
Party products in the marketplace, the patent and other proprietary position of the product, the likelihood of regulatory approval given the Regulatory Authority involved, the profitability of the product including the amounts payable to licensors
of patent or other intellectual property rights (it being understood that, because Epizyme is funding Abbott’s development of the Diagnostic Test, Abbott shall at all times exercise at least reasonable efforts with respect to the Diagnostic
Test notwithstanding profitability concerns, if any, and Abbott shall not reduce its efforts with respect to the Diagnostic Test pursuant to this Agreement based on opportunities to develop the Diagnostic Test or similar diagnostic products as
companion diagnostics for Third Party therapeutic products that are competitive with the Epizyme Product) and other relevant factors. Commercially Reasonable Efforts shall be determined on a market-by-market basis for a particular product, and it is
anticipated that the level of effort will be different for different markets, and will change over time, reflecting changes in the status of the product and the market(s) involved. For the avoidance of doubt, if an injunction issues based on any
intellectual property infringement alleged in the Enzo Lawsuit, as between Abbott and Epizyme, Abbott shall be solely responsible for, and shall use its commercially reasonable best efforts toward, either having such injunction lifted or obtaining a
license to the underlying intellectual property that is the basis for such injunction. 
 “Commercialization Lead” shall have
the meaning set forth in Section 4.5. 
 “Commercialization Plan” shall have the meaning set forth in Article 3.

 “Compound” shall mean Epizyme’s DOT1L inhibitor EPZ-5676 or, if Epizyme develops a successor compound in lieu of
EPZ-5676, such successor compound, it being understood that if a successor compound is pursued by Epizyme, appropriate changes to the Development Plan and payments to Abbott hereunder will be made pursuant to Sections 2.1 and 5.2. 

“Confidential Information” shall mean any and all non-public information, materials, data, samples, business plans, financial
information, marketing plans, reports, forecasts, technical or commercial information that is provided by Disclosing Party to a Receiving Party hereunder and which is either disclosed in writing and marked as confidential at the time of disclosure
or, if disclosed orally, referenced in writing and identified as confidential within a reasonable period of time following such oral disclosure; including any and all information regarding, related to, arising from or associated with this Agreement
or the activities contemplated hereby, the Compound, any Epizyme Product, the Diagnostic Test, Inventions, and the existence, terms and conditions of this Agreement. 

  
 3 

 “Control” or “Controlled” means, with respect to a Party and with respect
to an item of Abbott Technology or Epizyme Technology, as applicable, the possession, whether by ownership or license (other than pursuant to this Agreement), by such Party of the ability to grant to the other Party access and/or a license as
provided herein under such item or right without violating the terms of any agreement with any Third Party. 
 “Data” shall
mean any and all data, results, conclusions, reports, and other information generated by or for Epizyme resulting from the activities performed under the Development Plan. 
 “Development Lead” shall have the meaning as set forth in Section 4.5. 

“Development Plan” shall have the meaning as set forth in Article 2. 
 “Diagnostic Test” shall mean the MLL FISH assay to detect MLL break apart status in acute leukemia patients, developed by Abbott for the Diagnostic Test Intended Use and developed and
commercialized pursuant to the provisions of this Agreement. 
 “Diagnostic Test Intended Use” shall mean the identification of
patients who are appropriate candidates for treatment with an Epizyme Product for the Epizyme Product Indication, based on the use of the Diagnostic Test to identify such patients as approved by a Regulatory Authority. 

“Diagnostic Test Trademarks” shall mean the Trademarks used in conjunction with the Diagnostic Test in the Territory (excluding, however
all Epizyme owned or Controlled Trademarks). 
 “Disclosing Party” shall have the meaning set forth in Section 6.1.

 “Effective Date” shall have the meaning set forth in the Preamble. 
 “EU” shall mean all member states of the European Union. 
 “Enzo
Lawsuit” means the lawsuit captioned Enzo Life Sciences Inc. v. Abbott Laboratories and Abbott Molecular Inc., filed in the United States District Court for the District of Delaware as case number 1:2013cv00225, and any lawsuit between or
among Enzo Life Sciences Inc., Abbott Laboratories and/or Abbott based on the same or similar underlying subject matter filed in any other jurisdiction. 
 “Epizyme” shall have the meaning set forth in the Preamble. 
 “Epizyme
Claim” shall have the meaning set forth in Section 10.2(a). 
 “Epizyme Inventions” shall have the meaning set
forth in Section 7.8(c). 
 “Epizyme Know-How” means all Know-How (i) existing now or at any time in the future, and
(ii) Controlled by Epizyme independent of this Agreement, and (iii) is necessary for the development or commercialization of the Diagnostic Test for the Diagnostic Test Intended Use. 

  
 4 

 “Epizyme Losses” shall have the meaning set forth in Section 10.2(a). 

“Epizyme Materials” shall meaning set forth in Section 2.2(a). 
 “Epizyme Party” shall have the meaning set forth in Section 10.2(a). 

“Epizyme Patent Rights” means all Patent Rights claiming or covering: (a) the use of Compound or Epizyme Product; and/or
(b) the use of the Diagnostic Test for the Diagnostic Test Intended Use, in each case Controlled now or at any time in the future by Epizyme independent of this Agreement. 
 “Epizyme Product” means any pharmaceutical or biological preparation in final form containing the Compound (i) for sale by prescription, over-the-counter or any other method; or
(ii) for administration to human patients in a clinical trial, including in each case any monotherapy containing the Compound, any combination product containing the Compound, or any concomitant administration of a preparation containing the
Compound or any other Epizyme DOT1L inhibitor with a preparation containing a small molecule or biological. 
 “Epizyme Product
Indication” means the treatment of acute leukemias resulting from MLL translocations, with a label claim for such Epizyme Product approved by a Regulatory Authority based on the therapeutic response of patients with acute leukemias. If
Epizyme develops an Epizyme Product for one or more additional indications, Abbott shall not have any obligation hereunder to develop the Diagnostic Test for such additional indication(s) unless and until appropriate changes to the Development Plan
and payments to Abbott hereunder are made pursuant to Sections 2.1 and 5.2. 
 “Epizyme Technology” shall mean, collectively,
Epizyme Patent Rights and Epizyme Know-How, to the extent such Epizyme Know-How specifically relates to the Compound or any Epizyme Product. 

“FDA” shall mean the United States Food and Drug Administration, or any successor agency thereto. 

“First Commercial Sale” shall mean with respect to the Diagnostic Test and any country in the Territory, the first commercial sale by
Abbott or its Affiliates, sublicensees or distributors of the Diagnostic Test in that country to a Third Party, after such Diagnostic Test has been granted final Regulatory Approval by the competent Regulatory Authorities in such country.

 “FISH” shall mean a process known as fluorescence in situ hybridization. 

“FISH Platform Technology” shall mean the FISH process technology and the FISH probe composition and manufacturing technology disclosed
and claimed in the United States patents listed in Exhibit A(1). 

  
 5 

 “Invention” shall mean and include any and all inventions and discoveries which are, or may
be, patentable or otherwise protectable under the patent or other intellectual property laws of any country, which are conceived or discovered by either Party, its Affiliates or sublicensees during its or their respective activities pursuant to the
Development Plan, the Regulatory Plan and the Commercialization Plan during the term of this Agreement. 
 “Joint Inventions”
shall have the meaning as defined in Section 7.8. 
 “Joint Patent Right” shall have the meaning as set forth in
Section 7.8. 
 “JSC” shall mean the Joint Steering Committee established pursuant to Article 4. 

“Know-How” shall mean technical and other information which is not in the public domain, including information comprising or relating to
concepts, discoveries, data (including raw data), designs, formulae, ideas, inventions, materials, methods, models, research plans, procedures, designs for experiments and tests and results of experimentation and testing, processes, laboratory
records, chemical, pharmacological, toxicological clinical, analytical and quality control data, pre-clinical, clinical and non-clinical trial data, case report forms, data analyses, reports, manufacturing data or summaries and information contained
in submissions to an information from ethical committees and Regulatory Authorities. Know-How includes documents containing Know-How, including any rights including trade secrets, copyright, database or design rights protecting such Know-How.

 “MLL” shall mean the human Mixed Linage Leukemia (MLL) gene. 
 “Non-Breaching Party” shall have the meaning set forth in Section 9.2. 

“Orange Book” shall mean the publication entitled “Approved Drug Products with Therapeutic Equivalence Evaluations (Orange
Book),” or any successor thereto, as published from time to time by the FDA. 
 “Party” or “Parties”
shall mean Epizyme or Abbott, or Epizyme and Abbott, as the context admits. 
 “Patent Right” shall mean any and all
(i) patents, (ii) pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisionals, renewals, and all patents granted thereon, (iii) all patents-of-addition,
reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term extensions, supplementary protection certificates or the equivalent thereof, and (iv) all foreign
counterparts of any of the foregoing. 
 “Payment Timetable” shall have the meaning set forth in Section 5.1. 

“Person” shall mean any natural person, corporation, unincorporated organization, partnership, association, joint stock company, joint
venture, limited liability company, trust or government, or any agency or political subdivision of any government, or any other entity. 

  
 6 

 “Project Timeline Leads” shall have the meaning set forth in Section 4.8. 

“Receiving Party” shall have the meaning set forth in Section 6.1. 
 “Regulatory Approvals” shall mean and include all licenses, permits, authorizations and approvals of, and all registrations, filings and other notifications to any Regulatory Authority,
governmental agency or department within the Territory (including applications therefore) necessary or appropriate for the development, testing, manufacture, production, distribution, marketing, sale and/or use, as applicable, of the Diagnostic Test
or any Epizyme Product in a particular country or region of the Territory. 
 “Regulatory Authority(ies)” shall mean any
national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity in each country of the world involved in the reviewing, granting or revoking of Regulatory Approvals for the
Diagnostic Test. 
 “Regulatory Plan” shall have the meaning set forth in Exhibit C. 

“Specifications” shall mean the specifications applicable to the Diagnostic Test as set forth in Exhibit A(2). The Specifications
may be amended, in writing, from time-to-time as deemed necessary by the JSC, provided both Parties consent in writing to such amendment. 

“Territory” shall mean the entire world. 
 “ThermoBriteTM” shall mean Abbott and Iris Sample Processing, Inc.’s co-branded programmable temperature controlled slide processing system, including any similar new and/or
successor system developed during the term of this Agreement. 
 “Third Party” means any Person other than Epizyme or Abbott
(or their respective Affiliates). 
 “Trademarks” shall mean all registered and unregistered trademarks (including all common
law rights thereto), service marks, trade names, brand names, logos, taglines, slogans, certification marks, Internet domain names, trade dress, corporate names, business names and other indicia of origin, together with the goodwill associated with
any of the foregoing and all applications, registrations, extensions and renewals thereof throughout the world, and all rights therein provided by international treaties and conventions. 
 “VP 2000TM” shall mean Abbott’s proprietary consolidated workstation for automated front-end fluorescence in situ hybridization processing, including any similar new and/or
successor system developed during the term of this Agreement. 

  
 7 

 ARTICLE 2 

DEVELOPMENT 
 2.1 Development Plan. Abbott shall use Commercially Reasonable Efforts to develop the Diagnostic Test and, with Epizyme’s cooperation, shall develop the Diagnostic Test pursuant to the
provisions of a development plan which shall set forth, inter alia: 
 (a) the activities to be performed
by each Party under the Development Plan; 
 (b) the timelines for each activity; 

(c) key assumptions underlying the Parties’ respective performance obligations under the Development Plan (the
“Key Assumptions”); and 
 (d) the specifications of the Diagnostic Test. 

(as amended from time to time, the “Development Plan”). The initial Development Plan is attached hereto as Exhibit B. The Parties
acknowledge that the initial Development Plan does not address all of the items set forth above, but the Parties agree that, as soon as practicable following the Effective Date, the initial Development Plan will be modified and made more
comprehensive pursuant to the provisions of this Agreement. Thereafter, as may be necessary from time-to-time, the Development Leads shall suggest appropriate revisions to the Development Plan to the JSC for its prior written review and approval. If
the JSC approves such revisions, and the Parties consent in writing to such revisions, then the JSC shall revise the Development Plan accordingly without need for amending this Agreement. The Parties shall not unreasonably withhold their consent to
appropriate Development Plan revisions. The revised Development Plan shall thereafter be the Development Plan for all purposes of this Agreement. The Parties shall each use their Commercially Reasonable Efforts to perform all of their obligations
under the Development Plan in compliance with Applicable Law. 
 2.2 Epizyme Materials. 

(a) Epizyme will furnish to Abbott certain quantities, and/or Abbott will procure certain quantities using Epizyme’s funds, of
clinical trial specimens and other biological and pharmaceutical materials, as agreed upon and set forth in the Development Plan, the Regulatory Plan or the Commercialization Plan (“Epizyme Materials”). For avoidance of doubt, if
Abbott procures specimens and other biological and pharmaceutical materials with its own funds, such materials shall not be Epizyme Materials, it being understood that, unless otherwise set forth in the Development Plan, specimens and other
biological and pharmaceutical materials required for the performance of the Development Plan will be presumed to be, and shall be, purchased by Abbott using Epizyme’s funds paid to Abbott in accordance with Section 5.1. Abbott will comply
with all Applicable Laws relating to the Epizyme Materials. Without limiting the foregoing, to the extent that the Epizyme Materials include human specimens, Epizyme represents and warrants to Abbott that either it has obtained all informed consents
and Institutional Review Board (IRB)/Ethics Committee (EC) approval(s) required by Applicable 

  
 8 

 
Law with respect to such Epizyme Materials procured by Epizyme or that it is not required under Applicable Law to obtain such informed consents and/or has received a waiver for consent from an
IRB/EC. 
 (b) Abbott agrees to retain possession of the Epizyme Materials and not to provide the Epizyme Materials to any Third
Party (except for Third Parties conducting clinical trials on Abbott’s behalf pursuant to this Agreement and for whose performance and compliance with the terms of this Agreement Abbott remains primarily liable to Epizyme) or to use or permit
the use of any of the Epizyme Materials for any purpose other than the development and commercialization of the Diagnostic Test for the Diagnostic Test Intended Use without Epizyme’s prior written consent. 

(c) It is not contemplated that Epizyme will transmit any data that identifies or could be used to identify an individual
(“Personal Data”). However, to the extent that Personal Data can be identified from Epizyme Materials, Abbott shall hold in confidence all Personal Data except as required or permitted under this Agreement, or to the extent
necessary to be disclosed to regulatory agencies as part of the review process. In addition, Abbott shall comply with all Applicable Laws with respect to the collection, use, storage, and disclosure of any Personal Data, including without
limitation, the U.S. Health Insurance Portability and Accountability Act (HIPAA) and the regulations promulgated thereunder. Abbott agrees to ensure that all appropriate technical and organization measures are taken to protect Personal Data against
loss, misuse, and any unauthorized, accidental, or unlawful access, disclosure, alteration, or destruction, including without limitation, implementation and enforcement of administrative, technical, and physical security policies and procedures
applicable to Personal Data. 
 2.3 Regulatory Approvals. 

(a) In addition to the responsibilities set forth in the Development Plan, Abbott shall use Commercially Reasonable Efforts to seek
Regulatory Approvals for the Diagnostic Test and, with Epizyme’s cooperation, shall obtain the necessary Regulatory Approvals in the countries agreed upon in the Regulatory Plan for the commercialization of the Diagnostic Test with the
Diagnostic Test Intended Use; provided that, Epizyme may from time to time during the term of this Agreement request that Abbott seek Regulatory Approvals in additional countries or that Abbott refrain from seeking Regulatory Approvals
in one or more of the agreed countries identified in the Regulatory Plan, and Abbott shall agree to amend the Regulatory Plan accordingly; provided further that, if Epizyme requests the addition of a country in which Abbott does
not then have a presence with any fluorescence in situ hybridization diagnostic test and Abbott does not wish to directly establish such a presence in such country, Abbott shall not be required to add such country to the Regulatory Plan, but Abbott
and Epizyme shall discuss in good faith alternative distribution arrangements that might facilitate obtaining Regulatory Approval for and the availability of the Diagnostic Test in such country. The Parties shall agree upon a priority list of
countries, from among the countries agreed upon in the Regulatory Plan, for which Abbott shall attempt to first obtain Regulatory Approvals. Abbott shall be responsible for the responsibilities set forth in Exhibit C (the “Regulatory
Plan”) with respect to obtaining and maintaining in good standing for the periods covered by the Development Plan and the Commercialization Plan all necessary Regulatory Approvals from the relevant Regulatory

  
 9 

 
Authorities that are required for the development, commercialization and sale of the Diagnostic Test pursuant to the Development Plan and the Commercialization Plan. The Parties acknowledge that
the initial Regulatory Plan may not address all steps necessary to obtain all of the necessary Regulatory Approvals, but the Parties agree that, as soon as practicable following the Effective Date, the initial Regulatory Plan will be modified and
made more comprehensive pursuant to the provisions of this Agreement. Thereafter, as may be necessary from time-to-time, the Regulatory lead representatives of each Party shall suggest appropriate revisions to the Regulatory Plan to the JSC for its
written review and approval. If the JSC approves such revisions, and the Parties consent in writing to such revisions, then the JSC shall revise the Regulatory Plan accordingly without need for amending this Agreement. The Parties shall not
unreasonably withhold their consent to appropriate Regulatory Plan revisions. The revised Regulatory Plan shall thereafter be the Regulatory Plan for all purposes of this Agreement. 

(b) Epizyme shall be responsible for reimbursing Abbott for the costs and expenses incurred by Abbott in obtaining all Regulatory
Approvals for the Diagnostic Test for the Diagnostic Test Intended Use that are approved by Epizyme; provided that, the budget for such costs (i) [**]. Abbott shall [**] Epizyme [**]. Epizyme will [**]. 

2.4 Rights of Reference. Epizyme hereby grants to Abbott a non-exclusive, non-transferable (except in connection with a permitted
assignment, sublicense or subcontract) “right of reference” (as defined in 21 CFR 314.3(b) and comparable regulations outside the United States) with respect to clinical trial Data and results related to any Epizyme Product and Controlled
by Epizyme, as necessary for Abbott and its permitted assigns and sublicensees to prepare and submit submissions to Regulatory Authorities and maintain Regulatory Approvals related to the Diagnostic Test and related matters. Abbott hereby
grants to Epizyme a non-exclusive, non-transferable (except in connection with a permitted assignment, sublicense or subcontract) “right of reference” (as defined in 21 CFR 314.3(b) and comparable regulations outside the United States)
with respect to Abbott’s clinical sample analytical trial data and results related to the Diagnostic Test, as necessary for Epizyme and its permitted assigns and sublicensees to prepare and submit submissions to Regulatory Authorities, and to
maintain Regulatory Approvals, related to any Epizyme Product and related matters. 
 2.5 [**]. In the event that [**], Epizyme
shall [**]. If within [**] Abbott [**] [**], Epizyme shall [**] Abbott [**] Epizyme [**] Abbott [**] Epizyme; provided that, Epizyme shall have [**], if any, and Epizyme shall [**] Abbott [**] with Epizyme [**]Epizyme [**]. 

ARTICLE 3 
 COMMERCIALIZATION 
 3.1 Commercialization Plan.
Abbott shall use Commercially Reasonable Efforts to make the Diagnostic Test commercially available in each country in which Regulatory Approval is obtained pursuant to the Regulatory Plan and, with Epizyme’s cooperation as appropriate and
agreed by Epizyme in Epizyme’s reasonable discretion, shall commercialize the Diagnostic Test pursuant to the provisions of a joint commercialization plan (the “Commercialization Plan”), which shall include the following:

 (a) the activities to be performed by each Party (and, in the case of Epizyme, if Epizyme has licensed to or is otherwise
collaborating with a Third Party with respect to the development or commercialization of the Epizyme Product in any country or territory, the activities to be performed by such Third Party) and the deliverables related thereto; 

  
 10 

 (b) the timelines for each activity under the Commercialization Plan; 

(c) the overarching commercialization strategy and commercial goals for the Diagnostic Test, including the availability and distribution
of the Diagnostic Test in each country for which Regulatory Approval is sought pursuant to the Regulatory Plan; 
 (d) customer
service; 
 (e) responsibilities for and restrictions on public relations activity/Direct-To-Consumer and other promotional
advertising activity; 
 (f) coordination of the pre-launch/launch and post launch of Abbott/Epizyme (and Third Party, if
applicable) sales teams and scientific teams; 
 (g) forecasting and measurement of sales and distribution data, including
reporting of sales units of the Diagnostic Test to Epizyme and the Epizyme Product to Abbott; 
 (h) the establishment of
“launch success factors” for each market. Such launch success factors shall be agreed upon by the Parties prior to any launch; 
 (i) activities to be performed post-launch to ensure ongoing alignment of the Diagnostic Test Intended Use and Epizyme Product Indication, including fulfilling any commitment(s) imposed by Regulatory
Authorities; 
 (j) plans for manufacturing and supplying the Diagnostic Test; and 

(k) plans for maintaining acceptable levels of regulatory and GMP/GLP compliance during development, manufacture and marketing of the
Diagnostic Test. 
 (as amended from time to time, the “Commercialization Plan”). The initial Commercialization Plan is
attached hereto as Exhibit D. The Parties acknowledge that the initial Commercialization Plan does not address all of the items set forth above, but the Parties agree that, as soon as practicable following the Effective Date, the initial
Commercialization Plan will be modified and made more comprehensive pursuant to the provisions of this Agreement. Thereafter, as may be necessary from time-to-time, in particular as the Diagnostic Test gets closer to commercialization, the
Commercialization Team Lead shall suggest appropriate revisions to the Commercialization Plan to the JSC for its prior written review and approval. If the JSC approves such revisions, and the Parties consent in writing to such revisions, then the
JSC shall revise the Commercialization Plan accordingly without need for amending this Agreement. The Parties shall not unreasonably withhold their consent to appropriate Commercialization Plan revisions.

  
 11 

 
The revised Commercialization Plan shall thereafter be the Commercialization Plan for all purposes of this Agreement. The Parties shall each use their Commercially Reasonable Efforts to perform
all of their obligations under the Commercialization Plan in accordance with generally accepted ethical, best sales and marketing practices and in compliance with Applicable Law. 

3.2 Forecasts. Prior to the anticipated commercial launch of the Diagnostic Test and periodically thereafter, Epizyme shall
provide Abbott with nonbinding epidemiologic data and/or market demand forecast information in Epizyme’s possession as may be reasonably agreed by the Parties via the JSC. Epizyme shall have no liability for the accuracy of any such data or
information that Epizyme provides. 
 3.3 Price of Diagnostic Test. The price charged for the Diagnostic Test will be
determined by Abbott in its reasonable discretion; provided that, Abbott shall use Commercially Reasonable Efforts to obtain appropriate pricing and reimbursement approvals for the Diagnostic Test in countries in which the Diagnostic
Test is commercialized and to price the Diagnostic Test in a manner consistent with market norms for the pricing of companion diagnostic products. If requested by Abbott, Epizyme shall reasonably cooperate with Abbott’s efforts to obtain
reimbursement approvals for the Diagnostic Test. 
 ARTICLE 4 

GOVERNANCE OF AGREEMENT 

4.1 Governance of Agreement. As set forth in this Article 4, the Parties agree to govern the Agreement by way of the following
five collaborative groups: (1) Joint Steering Committee; (2) Development and Commercialization Leads; (3) Team Leads; (4) Alliance Leads; (5) Project Timeline Leads. Charts showing such governance and roles and
responsibilities of each group are set forth in Exhibits F, G and H. 
 4.2 Joint Steering Committee. The Parties shall
form a Joint Steering Committee (the “JSC”), which shall have the primary role in monitoring and ensuring the overall success of the development and commercialization of the Diagnostic Test. The JSC shall be comprised of no more
than [**] professionally and technically qualified representatives, with [**] representatives from each Party and comprised of representatives with sufficient qualifications to make decisions regarding the Development Plan, Regulatory Plan and
Commercialization Plan, considering the stage of development or commercialization of the Diagnostic Test. The members of the JSC shall represent the following functional areas of each Party: (1) Research & Development;
(2) Commercial; (3) Regulatory/Clinical; and (4) Business Development. The JSC shall meet for the first time within [**] days after the Effective Date and thereafter at least [**] during the term of this Agreement, unless the Parties
or the JSC decide that more or less frequent meetings are required; provided, however, that in the event of an emergent situation, including a situation in which a decision by the JSC is required, a meeting shall be held within [**] business
days after written request for such meeting by either Party. Each Party shall appoint co-chairpersons of the JSC from among the members of the JSC, who shall be responsible for setting the agenda for and chairing JSC meetings. Each Party’s
representatives shall collectively have one vote on each matter that is decided by the JSC. Both votes of the Parties’ representatives shall be required for approval of all actions required of the JSC. In the event of an impasse, the matter
shall be 

  
 12 

 
resolved pursuant to Section 4.4. The organization of the meeting and the meeting place shall alternate between the offices of Epizyme in Cambridge, Massachusetts and the offices of Abbott
in Des Plaines, Illinois or as otherwise decided by the JSC. JSC meetings may be conducted in person, by telephone or videoconference as agreed by the JSC. Each Party shall provide the other Party with written notice of its representatives for the
JSC promptly after the Effective Date of this Agreement. Each Party may substitute or replace any of its representatives on the JSC at any time and for any reason upon written notice to the other Party. Additionally, Alliance Leads shall attend JSC
meetings as non-voting members, and each Party may invite a reasonable number of other guests to the meetings, in order to discuss special technical or commercial topics relevant to the applicable agenda; provided, that any guests are subject
to the confidentiality provisions set forth in Article 6. 
 4.3 JSC Responsibilities. The JSC’s activities shall
include the following responsibilities with regard to the Diagnostic Test: 
 (a) review, confirmation, modification and/or
update of the Development Plan, the Regulatory Plan and the Commercialization Plan, subject to final approval by the Parties; 

(b) monitoring of the development, regulatory and commercialization activities under the Development Plan, the Regulatory Plan and
Commercialization Plan, respectively; 
 (c) resolution of issues raised by the Alliance Leads; 

(d) exchange of development and commercialization information; and 

(e) alignment of the regulatory submissions and Regulatory Approvals between any Epizyme Product and the Diagnostic Test. 

The JSC shall keep accurate and complete confidential minutes of its meetings. The Alliance Leads shall be responsible for taking such minutes and
distributing them to the JSC members for their review and comment within [**] business days after the date of each meeting, and within [**] business days after the receipt thereof, the JSC members shall remit such minutes back to the Alliance Leads
with their comments, if any. The JSC members shall in good faith attempt as quickly as is reasonably possible to resolve any disputes as to the content of such minutes so as to have a final agreed version as quickly as is reasonably possible. Each
Party shall be responsible for all expenses incurred by its representatives on the JSC in connection with performing their duties hereunder, including all costs of travel, lodging and meals. For the avoidance of doubt, the JSC shall not have the
authority to amend this Agreement, and shall have authority to amend the Development Plan, the Regulatory Plan and/or the Commercialization Plan only as expressly set forth herein, with the written consent of the Parties. 

4.4 JSC Decisions. All decisions of the JSC shall be made in good faith in the interest of furthering the purposes of this
Agreement and the JSC members shall use their Commercially Reasonable Efforts to take decisions unanimously (but Section 4.1 shall apply if unanimity is not 

  
 13 

 
achieved). If the JSC is unable to agree on any matter, then either Party’s co-chairperson of the JSC may refer the disagreement to a meeting between the Chief Executive Officer of Epizyme
(currently Robert Gould) and the President of Abbott (currently John Coulter) which meeting shall take place as soon as practicable, but in no event later than [**] days after the date of the relevant referral. Notwithstanding the foregoing, except
as otherwise provided in this Agreement, following the foregoing referral and meeting, if such officers are unable to resolve the issue by mutual agreement: (a) Epizyme will have the unilateral right to make final decisions that solely impact
the development, manufacture or marketing of any Epizyme Product; and (b) Abbott will have the unilateral right to make final decisions that solely impact the development, manufacture or marketing of the Diagnostic Test; provided that neither
Party shall be entitled to make a unilateral decision which imposes an obligation on the other Party to take on a financial obligation or deviates from the previously approved Development Plan, Regulatory Plan or Commercialization Plan or which is
inconsistent with such Party’s obligations under this Agreement. A description of the escalation process is set forth in Exhibit G. Matters that remain unresolved after the escalation process set forth in Exhibit G and that are not subject to
resolution under either Party’s final decisionmaking authority may be submitted for resolution by either Party as set forth in Exhibit I. 
 4.5 Development and Commercial Leads. 
 (a) Each Party shall designate a
single individual to serve as its “Development Lead.” The Development Leads shall be the principal point of contact for each Party for matters relating to the Development Plan and shall be responsible for implementing and
coordinating, on a day-to-day basis, all development activities and facilitating the exchange of information between the Parties regarding the Development Plan. 
 (b) Each Party shall designate a single individual to serve as its “Commercialization Lead.” The Commercialization Leads shall be the principal point of contact for each Party for matters
relating to the Commercialization Plan and shall be responsible for implementing and coordinating, on a day-to-day basis, all commercialization activities and facilitating the exchange of information between the Parties regarding the
Commercialization Plan. 
 (c) Within [**] days after the Effective Date, each Party shall provide the other Party with the
names of its Commercialization Lead and Development Lead. Each Party may replace its Commercialization Lead and Development Lead at any time and for any reason upon written notice to the other Party. 

(d) The Development Leads from each Party and the Commercialization Leads from each Party, respectively, shall meet as soon as
practicable after the Effective Date and thereafter during the performance of the Development Plan, the Regulatory Plan and the Commercialization Plan, as applicable, at least [**] and at such additional times as the Parties reasonably deem
appropriate. Meetings of the Leads may be conducted in person, by telephone or videoconference as agreed by the Development Leads or the Parties. Additionally, the Development Leads (or their designees) shall maintain close regular communications
with each other as to the status of the ongoing and planned activities under the Development Plan, the Regulatory Plan and Commercialization Plan, as applicable. 

  
 14 

 4.6 Team Leads 

The Parties shall form smaller teams of employees who will work together on the following teams: Clinical, Regulatory, Quality, Supply
Chain, Reimbursement/Market Access, Business Development & Licensing, and others as defined by the project scope and as the Parties may agree to form (“Team”). Each Party shall designate a single individual to serve as Team Leads
for each Team. Each Team shall meet as frequently as the Team may decide. 
 4.7 Alliance Leads 

Each Party shall designate a single individual to serve as its “Alliance Lead.” The Alliance Leads shall be the
principal point of contact for each Party for matters relating to the overall governance of the collaboration, including leadership of team collaboration and interactions between the Parties, which includes scheduling, coordinating and attending JSC
meetings, drafting agendas, preparing and circulating minutes of JSC meetings, and assuring that there is clear and smooth communications between the Parties and coordination among the Development Leads, Commercialization Leads, Team Leads, Project
Timeline Leads and JSC. 
 4.8 Project Timeline Leads 

Each party shall designate an individual to serve as its “Project Timeline Lead.” The Project Timeline Leads will develop,
track and update the Project timelines for the development and commercialization of the Diagnostic Test and the Compound. The Project Timeline Leads will coordinate the timelines for the Diagnostic Test and the Compound to enable both Parties to
meet the contract deliverables. 
 4.9 Escalation. 

Any matter that cannot be received by unanimous consent of the relevant teams or team members, as the case may be, shall be submitted to
the relevant Alliance Leads for resolution and thereafter for further resolution in accordance with Sections 4.3 and 4.4 of the Agreement. The escalation structure described is attached in Exhibit G. 

4.10 Other Governance Matters 
 (a) Neither the Development Leads, Commercialization Leads, Team Leads, Alliance Leads, Project Timeline Leads nor the JSC shall have authority to amend this Agreement. None of the foregoing shall have
authority to amend the Development Plan, the Regulatory Plan or the Commercialization Plan, which may be modified only with the approval of the Parties as permitted pursuant to Sections 2.1, 2.3(a) or 3.1, as applicable. 

(b) Unless otherwise provided for herein, each Party shall be responsible for all expenses incurred by its employees in connection with
performing their duties hereunder, including all costs of travel, lodging and meals. 

  
 15 

 ARTICLE 5 

PAYMENTS 
 5.1 Payments. As consideration for Abbott’s activities under the Development Plan, the Clinical Plan and the Commercialization Plan, Epizyme shall remit to Abbott payments aggregating up to a
maximum of [**] U.S. Dollars ($[**]) (unless increased pursuant to Section 5.2) in accordance with the Payment Timetable. In addition, Epizyme shall pay to Abbott a non-refundable, irrevocable license fee of [**] U.S. Dollars ($[**]) within
[**] days after the Effective Date. All other payments shall be made in accordance with the Payment Timetable set forth in Exhibit E (the “Payment Timetable”) and subject to the following: 

(a) The aggregate payments for each Stage in the Payment Timetable shall be the Total amount set forth for such Stage in the Payment
Timetable, and such amounts shall be paid in [**]. 
 (b) Once [**], Abbott shall invoice Epizyme [**], with subsequent payments
invoiced thereafter [**]; provided that, [**] Section 5.1(d) below. For example, [**]. 
 (c) Payments for [**]. If Abbott
[**], Abbott shall [**], and Epizyme shall [**] Section 5.3. 
 (d) Abbott shall give Epizyme at least [**] days prior
written notice before commencement of each Stage in the Payment Timetable subsequent to Stage 1. 
 5.2 Additional
Payments. If circumstances arise that materially deviate from the Key Assumptions, and such circumstances result from factors outside the reasonable control of Abbott and are not a result of any failure by Abbott to perform in accordance with
this Agreement, then the Parties shall amend existing payments(s), to cover the additional costs, if any, resulting from such material deviation from the Key Assumptions; provided, however, that Abbott shall not be required to incur such
additional costs and Epizyme shall not be responsible for paying such additional costs until the Parties reach agreement as to an additional appropriate payments(s), or amendment to existing payments(s), to cover such costs. 

5.3 Invoices. Abbott shall invoice Epizyme for Payment Timetable payments in accordance with Section 5.1. Epizyme shall pay
all such invoices within [**] days of receipt in the manner described in Section 5.5. 
 5.4 Bridging, Clinical Trial
Site Cost and Regulatory Cost Payments. In addition to the payments set forth in Section 5.1 and 5.2, Epizyme shall pay, or reimburse Abbott for, one hundred percent (100%) of (a) all Bridging and Clinical Trial Site Costs for the
first Epizyme Product and (b) costs and expenses incurred by Abbott in obtaining Regulatory Approvals in accordance with Sections 2.3(a) and 2.3(b). Epizyme shall pay all such invoices for such costs and expenses within [**] days of receipt
thereof in the manner described in Section 5.5. 

  
 16 

 5.5 Payment Terms. The payment terms for all payments shall be as follows:

 (a) Payments are payable within [**] days after Epizyme’s receipt of an invoice from Abbott. 

(b) All payments by Epizyme to Abbott under this Agreement shall be made in U.S. Dollars to the following account: 

Northern Trust Company 
 Chicago, Illinois, USA 
 ABA: 071000152 

SWIFT Code: CNORUS44 
 Account Name: Abbott Laboratories Inc. 
 Account Number: [**]

 (c) If applicable laws, rules or regulations require the withholding of taxes, Epizyme shall make such withholding payments
and shall subtract the amount thereof from the applicable payments hereunder. Epizyme shall submit to Abbott appropriate proof of payment of the withheld taxes as well as the official receipts within a reasonable period of time. Epizyme shall
provide Abbott reasonable assistance in order to allow Abbott to obtain the benefit of any present or future treaty against double taxation which may apply to the applicable payments hereunder. 

ARTICLE 6 
 CONFIDENTIALITY, PUBLICITY AND PUBLICATIONS 
 6.1 Confidentiality. As of and after the Effective Date, all Confidential Information disclosed, revealed or otherwise made available by one Party (“Disclosing Party”) to the other
Party (“Receiving Party”) under, or as a result of, this Agreement is furnished to the Receiving Party solely to permit the Receiving Party to exercise its rights, and perform its obligations, under this Agreement. The Receiving
Party shall not use any of the Disclosing Party’s Confidential Information for any other purpose, and shall not disclose, reveal or otherwise make any of the Disclosing Party’s Confidential Information available to any other person, firm,
corporation or other entity, without the prior written authorization of the Disclosing Party. As of and after the Effective Date all exchanges of Confidential Information shall be governed by the provisions of this Agreement and no longer by the CDA
(which shall remain in effect pursuant to the provisions thereof with respect to all exchanges of Confidential Information prior to the Effective Date). 
 6.2 Safeguarding of Confidential Information. In furtherance of the Receiving Party’s obligations under Section 6.1, the Receiving Party shall protect the Disclosing Party’s
Confidential Information to the same extent it protects its own confidential information of like kind and sensitivity. Without limiting the generality of this Section 6.2, the Receiving Party shall disclose any of the Disclosing Party’s
Confidential Information only to those of its officers, 

  
 17 

 
employees, licensees, sublicensees, consultants, and attorneys that have a need to know the Disclosing Party’s Confidential Information, in order for the Receiving Party to exercise its
rights and perform its obligations under this Agreement, and only if such officers, employees, licensees, sublicensees, consultants, attorneys and financial advisors have executed appropriate non-disclosure agreements containing substantially
similar terms regarding confidentiality as those set out in this Agreement or are otherwise bound by obligations of confidentiality effectively prohibiting the unauthorized use or disclosure of the Disclosing Party’s Confidential Information.
The Receiving Party shall promptly furnish the Disclosing Party with written notice of any known unauthorized use or disclosure of any of the Disclosing Party’s Confidential Information by any officer, employee, licensee, sublicensees,
consultants, attorneys or financial advisors of the Receiving Party, and shall take all actions that the Disclosing Party reasonably requests in order to prevent any further unauthorized use or disclosure of the Disclosing Party’s Confidential
Information. 
 6.3 Exceptions. Confidential Information shall not include information that: 

(a) is or becomes publicly available through no breach of this Agreement by the Receiving Party; 

(b) was known to the Receiving Party prior to disclosure hereunder by the Disclosing Party (as evidenced by the Receiving Party’s
written records); 
 (c) is disclosed, revealed or otherwise made available to the Receiving Party by a Third Party that, to the
Receiving Party’s knowledge, is under no obligation of confidentiality relating to such information; or 
 (d)
Notwithstanding the provisions of Section 6.2, a Receiving Party may disclose Confidential Information if such Receiving Party is required to disclose such Confidential Information under Applicable Law, or in connection with any application by
the Receiving Party for any Regulatory Approvals; provided, however, that the Receiving Party shall furnish the Disclosing Party with as much prior written notice of such disclosure requirement as reasonably practicable, so as to permit the
Disclosing Party, in its sole discretion, and at its sole expense, to take appropriate action, including seeking a protective order, in order to prevent the Disclosing Party’s Confidential Information from passing into the public domain or
becoming generally available to the public. Such Confidential Information disclosed pursuant to this paragraph shall remain Confidential Information under this Agreement despite such required disclosure, unless the exceptions set forth in
Section 6.3(a) through (c) apply. 
 6.4 Term of Confidentiality Obligations. All of the Receiving Party’s
obligations under Sections 6.1 and 6.2 with respect to the protection of the Disclosing Party’s Confidential Information shall survive for a period of [**] years following the expiration or termination of this Agreement for any reason.

 6.5 Publicity. No public announcement concerning the existence or terms of this Agreement shall be made, either
directly or indirectly, by either Party, without first obtaining the prior written approval of the other Party and agreement upon the nature and text of such public 

  
 18 

 
announcement. Notwithstanding the foregoing, if, in the opinion of legal counsel for the Party desiring to make such public announcement, such disclosure is required under Applicable Law, subject
to Section 6.3(c) above, the Party required to make such public announcement shall inform the other Party of the proposed announcement or disclosure in reasonably sufficient time prior to public release, which shall be not less than [**]
business days (or such shorter period as may be required under Applicable Law) prior to release of such proposed public announcement, and shall provide the other Party with a written copy thereof in order to allow such other Party to comment upon
such public announcement. The Receiving Party shall reasonably cooperate with the Disclosing Party (at the Disclosing Party’s expense) with respect to all disclosures regarding this Agreement required under Applicable Law, including requests
for confidential treatment of proprietary information of the Disclosing Party included in any such disclosure. Notwithstanding the foregoing, the Parties shall mutually agree upon the form and substance of, and release, separate press release(s)
announcing their development relationship regarding the Diagnostic Test pursuant to this Agreement upon the initial use of the Diagnostic Test in a phase II registrational trial of the Epizyme Product. Any future press releases will remain subject
to this Section 6.5. 
 6.6 Applicable Law. Nothing in this Agreement shall be construed as preventing or in any way
inhibiting either Party from complying with Applicable Law governing activities and obligations undertaken pursuant to this Agreement, in any manner which it reasonably deems appropriate, including, for example, by disclosing to Regulatory
Authorities confidential or other information received from the other Party, subject to Section 6.3(d) and 6.5. 
 6.7
Non-Use of Names. Except as otherwise provided in this Agreement, neither Party (or its Affiliates) shall use, either directly or indirectly, the names of any of their officers, employees or board members in any publicity, marketing
advertising or other documents (or other disclosures) unless a copy or transcript of the proposed disclosure is submitted to and approved in advance in writing by the other Party (in its sole discretion), except in the case in which a governmental
authority requires the use in the sale or distribution of the Diagnostic Test or any Epizyme Product. Each Party will use Commercially Reasonable Efforts to review and approve any proposed disclosure within [**] business days of its receipt from the
other Party of a copy or transcript of the proposed disclosure. If a Party approves the other Party’s usage of the names of any of their officers, employees or board members in accordance with this Section 6.7, the other Party shall comply
with any usage guidelines or requirements imposed by the approving Party. 
 6.8 Publications. Epizyme and Abbott each
acknowledge the other Party’s interest in publishing the results of its research in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in
obtaining valid patent protection and in protecting business interests and trade secret information. Consequently, except for disclosures permitted pursuant to Section 6.3, either Party, its employee(s) or consultant(s) wishing to make a
publication in a journal, paper, magazine or presentation relating to the Diagnostic Test shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least [**] days prior to submission for
publication (or in the case of an abstract or presentation at least [**] days prior to submission of such abstract for publication or the making of such presentation). The reviewing 

  
 19 

 
Party shall have the right (a) to propose modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable
delay in publication or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party shall delay submission or presentation for a period of [**] days to enable patent applications protecting
each Party’s rights in such information to be filed in accordance with the laws governing intellectual property protection. Upon expiration of such [**] days, the publishing Party shall be free to proceed with the publication or presentation.
If the non-publishing Party requests modifications to the publication or presentation, the publishing Party shall edit such publication or presentation to prevent disclosure of trade secret or proprietary business information Controlled by the
non-publishing Party prior to submission of the publication or presentation. Epizyme’s and/or Abbott’s contribution shall be acknowledged in any publication by co-authorship or acknowledgment, whichever is appropriate. 

ARTICLE 7 
 INTELLECTUAL PROPERTY 
 7.1 License
Grants. 
 (a) Abbott grants to Epizyme, as of the Effective Date a perpetual, royalty-free non-exclusive license in the
Territory under the Abbott Patent Rights and Abbott Know-How to research, develop, make, have made, use, sell, offer for sale and import any Epizyme Product. Subject to Section 7.6, Abbott further grants to Epizyme, as of the Effective Date, a
royalty-free, non-exclusive, perpetual license to refer to or recommend the use of the Diagnostic Test in Epizyme’s label, package insert, promotional or regulatory material for any Epizyme Product in each country of the Territory in which
Epizyme has obtained Regulatory Approval for any Epizyme Product. 
 (b) Epizyme grants to Abbott, as of the Effective Date, a
perpetual royalty-free non-exclusive license in the Territory under the Epizyme Patent Rights, Epizyme Know-How and Epizyme Inventions to research, develop, make, have made, use, sell, offer for sale and import the Diagnostic Test for the Diagnostic
Test Intended Use. Subject to Section 7.6, Epizyme further grants to Abbott, as of the Effective Date, a royalty-free, non-exclusive, perpetual license in the Territory to refer to the Compound and any Epizyme Product, as may be required
pursuant to Applicable Law, in Abbott’s label, package insert, promotional or regulatory material for the Diagnostic Test in each country of the Territory in which Abbott has obtained Regulatory Approval for the Diagnostic Test. 

(c) Epizyme and Abbott each grant to the other, a perpetual, royalty-free non-exclusive license (without the right to grant sublicenses
except to Affiliates) in the Territory under the Epizyme Technology and Abbott Technology, respectively, to perform such other Party’s obligations under this Agreement. 
 7.2 Right to Sublicense. Both Parties shall be entitled to sublicense all or any of their rights under Section 2.4, Section 7.1(a) and Section 7.1(b) (subject to any applicable
restrictions on any intellectual property in-licensed from Third Parties) (i) to their respective Affiliates, and (ii) to Third Party contractors used in the development, manufacturing and commercialization of

  
 20 

 
the Diagnostic Test or any Epizyme Product, as applicable, (iii) in the case of Epizyme, to a Third Party that acquires the exclusive rights in a country to develop or commercialize an
Epizyme Product or is a party to a collaboration with Epizyme or another Third Party with respect to the development or commercialization of an Epizyme Product in a country, and (iv) in the case of Abbott, to a Third Party that acquires the
exclusive, rights in a country to develop or commercialize the Diagnostic Test. 
 7.3 License to Data. Epizyme hereby
grants to Abbott a perpetual, non-exclusive, non-transferable (except in connection with a permitted assignment, sublicense or subcontract) royalty-free license under the Data as necessary for Abbott to research, develop and commercialize the
Diagnostic Test for the Diagnostic Test Intended Use and to use Data as necessary in patent filings with respect to the Diagnostic Test for the Diagnostic Test Intended Use. 
 7.4 Further Actions. Each Party shall execute all documents and give all declarations regarding the licenses granted in Section 7.1 and reasonably cooperate with the other Party, to the extent
such documents, declarations and/or cooperation are reasonably required for the recording or registration of the licenses granted hereunder at the various intellectual property offices in the Territory for the benefit of the licensee Party.

 7.5 No Other Licenses. Nothing in this Agreement shall be deemed or implied to be, and the Parties disclaim all
implied rights to, the grant by either Party to the other Party of any license, right, title or interest in either Party’s product, intellectual property rights (including Patent Rights, Know-How, trade secrets, copyrights, and Trademarks), any
formulation technology or know-how, manufacturing technology or know-how, operating procedures, marketing materials or strategies, intangibles, material or proprietary rights or any other tangible or intangible property, except as are expressly set
forth in this Agreement. 
 7.6 Trademarks. 
 (a) Abbott shall own all right, title and interest in and to any Trademarks developed by or for Abbott for use in connection with the Diagnostic Test (“Abbott’s Trademarks”). Abbott hereby
grants to Epizyme a royalty-free non-exclusive license to use Abbott’s Trademarks for the purpose of referring to the Diagnostic Test in connection with advertising and marketing any Epizyme Product. Any and all goodwill derived from the use of
Abbott’s Trademarks shall inure solely to the benefit of Abbott. 
 (b) Epizyme shall own all right, title and interest in
and to all Trademarks developed by or for Epizyme for use in connection with any Epizyme Product (“Epizyme’s Trademarks”). Epizyme hereby grants to Abbott a royalty-free non-exclusive license to use Epizyme’s Trademarks for the
purpose of referring to Epizyme Products in connection with advertising and marketing the Diagnostic Test. Any and all goodwill derived from the use of Epizyme’s Trademarks shall inure solely to the benefit of Epizyme. 

(c) Each party agrees that the use of the other Party’s Trademarks in connection with advertising and marketing the Diagnostic Test
or any Epizyme Product shall be in accordance with the terms of this Agreement and shall comply with all federal, state and local laws and regulations. 

  
 21 

 1. Approval of Trademark Use. 

(a) Each party agrees to provide artwork for any packaging, labeling and promotional materials that display the other Party’s
Trademarks for approval prior to any use or distribution of such materials. Each party shall respond in writing with its approval or requested changes, such approval not to be unreasonably withheld, within [**] business days after receipt of such
artwork from the other Party. 
 (b) Once a proposed use of the Trademarks has been approved by the Party that is the licensor,
and provided that the Party that is the licensee does not make any changes to the presentation of the Trademarks in such approved product packaging, labeling or promotional materials, the Party using the Trademarks under license may utilize the same
approved presentation in other product packaging, labeling or promotional materials. 
 (d) Each party will refrain from any use
of the other’s Trademarks in a manner that threatens to damage the goodwill associated with the respective Trademarks or which threatens to tarnish the reputation or otherwise reflect unfavorably upon the owner of the Trademarks. 

(e) Epizyme shall not, during or after the term of the Agreement, anywhere in the world, take any action that in Abbott’s sole and
absolute discretion impairs or contests or tends to impair or contest the validity of Abbott’s right, title and interest in and to Abbott’s Trademarks, including, but not limited to, using, or filing an application to register, any word,
mark, symbol or device, or any combination thereof, that is confusingly similar to or dilutes the distinctiveness of any of Abbott’s Trademarks. 
 (f) Abbott shall not, during or after the term of the Agreement, anywhere in the world, take any action that in Epizyme’s sole and absolute discretion impairs or contests or tends to impair or
contest the validity of Epizyme’s right, title and interest in and to Epizyme’s Trademarks, including, but not limited to, using, or filing an application to register, any word, mark, symbol or device, or any combination thereof, that is
confusingly similar to or dilutes the distinctiveness of any of Epizyme’s Trademarks. 
 (g) If either Epizyme or Abbott
becomes aware of any infringement of the other’s Trademarks, anywhere in the world, it will promptly notify the other Party in writing. Each Party agrees to fully cooperate with the Party that is the owner of the Trademarks regarding any action
the owner may take with respect to such infringement or violation. The Party that is the owner of the Trademarks shall have the exclusive right, exercisable in its sole and unlimited discretion, to institute in its own name and to control all
actions against Third Parties relating to such Trademarks, at the owner’s expense. The Party that is the owner of the Trademarks shall be entitled to receive and retain all amounts awarded, if any, as damages, profits or otherwise in connection
with such actions. 

  
 22 

 7.7 Ownership of Existing Technology. As between the Parties, Abbott shall retain
sole and exclusive ownership of the Abbott Technology. As between the Parties, Epizyme shall retain sole and exclusive ownership of the Epizyme Technology. 
 7.8 Inventions. 
 (a) All Inventions shall be promptly disclosed to the
other Party hereto in confidence and in writing. 
 (b) Abbott shall have exclusive ownership of and title to any and all
Inventions solely related to the Abbott Technology, the Diagnostic Test, and the Abbott Diagnostics and to all intellectual property rights solely related thereto or arising therefrom (“Abbott Inventions”), that are discovered or
reduced to practice solely by employees or agents of either Party, or jointly by employees or agents of either Party, during the term of this Agreement. Abbott shall have the sole right, but not the obligation, to file for, prosecute, maintain,
enforce and defend any and all Patent Rights claiming the Abbott Inventions, and shall have the right, in its sole discretion, whether or not, or where, to file a patent application, to abandon the prosecution of any patent or patent application, to
discontinue the maintenance of, or enforce any such patent or patent application within the Abbott Patent Rights. 
 (c) Epizyme
shall have exclusive ownership of and title to the Data and all Inventions solely related to the Epizyme Technology, the Compound and any Epizyme Product, and to all intellectual property rights related thereto or arising therefrom (“Epizyme
Inventions”), that are discovered or reduced to practice solely by employees or agents of either Party, or jointly by employees or agents of either Party, during the term of this Agreement. Epizyme shall, at its own cost, have the sole
right, but not the obligation, to file for, prosecute, maintain, enforce and defend any and all patents claiming the Epizyme Inventions, and shall have the right, in its sole discretion, whether or not, or where, to file a patent application, to
abandon the prosecution of any patent or patent application, to discontinue the maintenance of, or to enforce any such patent or patent application. 
 (d) As for all Inventions not covered by Section 7.8(b) or Section 7.8(c), the ownership and title thereto (including the ownership and title to all intellectual property rights related thereto
or arising there from) shall be based on inventorship, as determined pursuant to the inventorship principles arising under the patent laws of the United States of America, and any such Inventions having an employee and/or collaborator of each Party
as co-inventors shall be “Joint Inventions.” [**]: 
 (i) [**]. 

(ii) [**]. Epizyme [**] Epizyme [**] Epizyme [**]Epizyme [**] and [**] Epizyme; and [**] Epizyme [**]. Epizyme shall [**] Abbott
[**], and shall [**] Abbott [**]; provided such [**]. 

  
 23 

 (e) Neither Party shall be entitled to use or exploit any Joint Invention without the prior
written consent of the other Party except that: (i) each Party shall be entitled to use in the Territory, without consideration to the other Party, any Joint Inventions in its internal research programs, including research performed under
confidentiality agreements with Third Party collaborators, without the right to sublicense or commercialize such Joint Invention without the other Party’s prior written consent, and with the other Party receiving a non-exclusive, royalty-free
license to use any subsequent inventions directly resulting from the use of such Joint Invention in its internal research programs; (ii) each Party shall be entitled to use in the Territory any Joint Inventions for the purpose of performing its
obligations under this Agreement, without consideration to the other Party; (iii) Epizyme and its Affiliates shall be entitled to use in the Territory any Joint Inventions without the prior written consent of Abbott, without consideration to
Abbott, and without accounting to Abbott, to make, have made, use, have used, sell, have sold, offer for sale, and import the Compound and any Epizyme Product and to exercise the rights and licenses set forth in Section 7.8(d), including the
right to sublicense Third Parties under such rights and licenses as set forth in Section 7.8(d); and (iv) Abbott and its Affiliates shall be entitled to use in the Territory any Joint Inventions without the prior written consent of
Epizyme, without consideration to Epizyme, and without accounting to Epizyme, to make, have made, use, have used, sell, have sold, offer for sale, and import diagnostic tests. 
 (f) If the Parties create a Joint Invention, the Parties shall promptly meet to discuss and decide whether to seek patent protection therefore (“Joint Patent Right”). If the Parties
decide to seek patent protection on a Joint Invention, Epizyme has the first right, at its own expense, to prepare, file, prosecute and maintain any Joint Patent Right throughout the world on behalf of both Parties. Epizyme shall give Abbott an
opportunity to review and comment on any patent application with respect to such Joint Patent Right before filing, shall consult with Abbott with respect thereto, and shall supply Abbott with a copy of the patent application as filed, together with
notice of its filing date and serial number. Epizyme shall keep Abbott advised of the status of the actual and prospective patent filings. Preparation, filing, prosecution and maintenance of such Joint Patent Rights will be handled by patent counsel
acceptable to both Parties. If Epizyme elects not to file a patent application on a Joint Invention or to cease the prosecution and/or maintenance of any Joint Patent Right in any country of the Territory, Epizyme shall provide Abbott with written
notice upon the decision to not file or continue the prosecution of such application or maintenance of such Joint Patent Right, in any event not later than [**] days before any relevant deadline relating to or any public disclosure or loss of the
relevant Joint Patent Rights. In such event, Epizyme shall permit Abbott to file and/or continue prosecution and/or maintenance of such Joint Patent Rights in the names of both Parties but at Abbott’s own expense. Epizyme agrees to provide
documents and perform such acts, at Epizyme’s expense, as may be reasonably necessary to permit Abbott to file, prosecute and/or maintain such Joint Patent Rights. 
 (g) If either Epizyme or Abbott becomes aware of any infringement, anywhere in the world, of any issued patent within the Joint Patent Rights, it will promptly notify the other Party in writing to that
effect. 
 (h) Epizyme shall have the first right, but not the obligation, to take action to obtain a discontinuance of
infringement or bring suit against a Third Party infringer of any Joint 

  
 24 

 
Patent Rights within [**] days from the date of notice and to join Abbott as a party plaintiff. Epizyme shall bear all the expenses of any suit brought by it claiming infringement of any Joint
Patent Right. Abbott will reasonably cooperate with Epizyme, at Abbott’s expense, in any such suit and shall have the right to consult with Epizyme and to participate in and be represented by independent counsel in such litigation at its own
expense. If, after the expiration of such [**]-day period (or, if earlier, the date upon which Epizyme provides written notice that it does not plan to bring suit), Epizyme has not obtained a discontinuance of infringement of the Joint Patent Right
or filed suit against any such Third Party infringer of the Joint Patent Right, then Abbott shall have the right, but not the obligation, to bring suit against such Third Party infringer of the Joint Patent Right, provided that Abbott shall
bear all the expenses of such suit, and further provided that such infringement is not the result of a notice to Epizyme from such Third Party infringer under 21 U.S.C. §355(b)(2)(A)(iv) or 355(j)(2)(A)(vii)(IV) (“Paragraph IV
Notice”) with respect to any Joint Patent Right and any Epizyme product for which Epizyme holds an approved New Drug Application. Epizyme will reasonably cooperate with Abbott, at Epizyme’s expense, in any such suit for infringement of
a Joint Patent Right brought by Abbott against a Third Party, and shall have the right to consult with Abbott and to participate in and be represented by independent counsel in such litigation at its own expense. Any recoveries obtained by Epizyme
or Abbott, as applicable, as a result of any proceeding against such a Third Party infringer shall be allocated as follows: (A) such recovery shall first be used to reimburse each Party for all reasonable attorney fees and other litigation
costs actually incurred in connection with such litigation by that Party, and (B) any remainder shall be allocated [**] percent ([**]%) to the enforcing Party and [**] percent ([**]%) to the non-enforcing Party; provided, however, that
Epizyme shall be entitled to retain all such recoveries if the proceeding against a Third Party infringer is a result of the Third Party’s filing of a Paragraph IV Notice with respect to a Epizyme product for which Epizyme holds an approved New
Drug Application. 
 (i) Abbott and Epizyme agree to cooperate with respect to filing for and prosecuting any application for
patent term extension of any Joint Patent Right to the extent such patent term extension is not based on the approval of any New Drug Application or any other regulatory approval for an Epizyme Product (“Term Extension”). Epizyme
shall have the first right, but not the obligation, to file and prosecute a Term Extension, at its sole cost and expense. Where Epizyme decides not to file for a Term Extension, it shall provide Abbott written notice thereof at least [**] days
before the deadline for filing a Term Extension for the particular Joint Patent Right. After such notice, Abbott shall have the right, but not the obligation, to file and prosecute a Term Extension, at its sole cost and expense. The party
prosecuting a Term Extension will keep the other party apprised of the prosecution. For the avoidance of doubt, Epizyme shall have no obligation to seek or permit Abbott to seek any patent term extension relating to any regulatory approval of an
Epizyme Product. 
 (j) Abbott agrees that Epizyme shall have the right to list any Joint Patent Right in an Orange Book filing
for the Compound and any Epizyme Product, in its sole discretion, where Epizyme reasonably determines the particular Joint Patent Right is eligible for listing in the Orange Book as applicable to the Compound or any Epizyme Product. 

7.9 Additional Documents. Each Party agrees to cooperate reasonably and in good faith in the execution and filing of any necessary
applications, assignments, powers of attorney, 

  
 25 

 
or other filings or documents as may be reasonably deemed necessary by the other Party to vest in and ensure the proper ownership, Control, and maintenance of the Inventions pursuant to this
Article 7, and each Party shall obtain the cooperation of its employees or agents to execute the same. 
 7.10 Notification
of Infringement; Third Party License. If the making, having made, importing, exporting, using, distributing, marketing, promoting, offering for sale or selling of the Diagnostic Test is alleged by a Third Party to infringe a Third Party’s
intellectual property rights, the Party becoming aware of such allegation shall promptly notify the other Party. Additionally, if either Party determines that, based upon the review of a Third Party’s intellectual property rights, it may be
desirable to obtain a license from such Third Party with respect thereto; such Party shall promptly notify the other Party of such determination. The Parties shall work together toward a resolution of any Third Party claim or potential claim.

 ARTICLE 8 
 REPRESENTATIONS, WARRANTIES AND COVENANTS 
 8.1 General. Each of Abbott and Epizyme hereby represents, warrants and covenants to the other Party as follows as of the Effective Date: 

(a) it is a corporation or entity duly organized and validly existing under the laws of its state of incorporation; 

(b) the execution, delivery and performance of this Agreement by such Party does not conflict with any other agreement by which it is
bound, and has been duly authorized by all requisite corporate action and does not require any shareholder action or approval; 

(c) it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and 

(d) it shall at all times comply with all Applicable Laws relating to its activities under this Agreement. 

8.2 Intellectual Property. Each Party hereby represents and warrants that as of the Effective Date it currently owns and/or has
(other than the Trademarks for use in connection with the Diagnostic Test, which will be developed by or for Abbott after the Effective Date and the Trademarks for use in connection with the Epizyme Product, which will be developed by or for Epizyme
after the Effective Date), and will maintain throughout the term of this Agreement, the right and ability to grant the other Party the licenses under its intellectual property that are set forth in this Agreement. Nothing in this Agreement shall be
construed as a warranty by either Party that their respective intellectual property rights will be valid or enforceable, provided, however, that each Party hereby represents and warrants to the other Party that it has no present actual
knowledge that: (a) its intellectual property rights are or will be invalid or unenforceable; (b) any Third Party intellectual property rights are infringed (or alleged to be infringed, except as alleged in the Enzo Lawuit) by the practice
of such Party’s intellectual property rights; or (c) any Third Party is infringing such Party’s intellectual property rights. 

  
 26 

 8.3 Disclaimer. EXCEPT FOR THE
EXPRESS REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS AGREEMENT, NEITHER ABBOTT
NOR EPIZYME MAKES, AND EACH HEREBY EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR
WARRANTIES, EITHER EXPRESS OR IMPLIED, WHETHER IN FACT OR IN LAW,
INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, OR NON-INFRINGEMENT. 
 8.4 No Representations Regarding
Approval or Commercial Success. Neither Party makes any representations or warranties as to: (a) whether the any Epizyme Product or the Diagnostic Test will be approved for commercial sale by the applicable Regulatory Authorities; or
(b) the commercial potential or success of any Epizyme Product or the Diagnostic Test. 
 8.5 Other Indications. If
Epizyme develops an indication for the Compound or any Epizyme Product other than an acute leukemia, the Parties shall each in good faith consider either amending this Agreement to include such indication or entering into another similar agreement
related to such indication. The Parties agree that any such amendment or other agreement remains subject to the Parties reaching a mutually acceptable agreement on such terms and conditions and the receipt of all necessary management approvals by
each of the Parties. 
 ARTICLE 9 
 TERM AND TERMINATION 
 9.1
Term. This Agreement shall become effective as of the Effective Date. Unless earlier terminated pursuant to the provisions of this Article 9, this Agreement shall remain in full force and effect on a country-by-country basis until the date on
which Epizyme ceases to market an Epizyme Product in such country of the Territory. 
 9.2 Breach. If either Party (the
“Breaching Party”) commits a material breach or default of any of its obligations hereunder, the other Party hereto (the “Non-Breaching Party”) may give the Breaching Party written notice of such material breach or
default. If the Breaching Party fails to cure such breach or default within [**] days after the date of the Non-Breaching Party’s notice thereof, the Non-Breaching Party may terminate this Agreement upon written notice to the Breaching Party.
If the Breaching Party indicates in writing that it will be unable or is unwilling to cure the breach, this Agreement may be terminated by the Non-Breaching Party with immediate effect. 

9.3 Bankruptcy or Insolvency. Each Party shall have the right to terminate this Agreement, immediately by giving written notice of
termination to the other Party, if the other Party files a voluntary petition, or if an involuntary petition is granted in respect of the other Party and appeal proceedings are not commenced within ten (10) business days from the date of such
petition under the bankruptcy provisions of Applicable Law, or the other Party is declared insolvent, undergoes voluntary or involuntary dissolution, or makes an assignment for the benefit of its creditors, or is unable to pay its debts as they come
due, or suffers the appointment of a 

  
 27 

 
receiver or trustee over all, or substantially all, of its assets or properties. All rights and licenses granted under or pursuant to this Agreement by Abbott to Epizyme, and by Epizyme to
Abbott, are, and shall otherwise be deemed to be, for purposes of Article 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Article 101(52) of the U.S. Bankruptcy Code. The Parties agree
that each Party, as a licensee of such intellectual property rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. 

9.4 Injunction. 
 (a) Abbott may terminate this Agreement upon providing Epizyme ninety (90) days prior written notice if: (i) Abbott’s making, having made, importing, exporting, using, distributing,
marketing, promoting, offering for sale or selling the Diagnostic Test for the Diagnostic Intended Use; or (ii) Epizyme’s offering for sale or selling the Epizyme Product, in either case ((i) or (ii)) is (x) enjoined by a court of
competent jurisdiction because such enjoined activity actually or allegedly infringes or misappropriates a Third Party’s intellectual property rights, (y) such actual or alleged infringement or misappropriation is not infringement or
misappropriation for which Abbott is obligated to indemnify Epizyme pursuant to Section 10.2(b), and (z) during such ninety (90) day period, Epizyme is unable or unwilling to obtain a license to the applicable Third Party intellectual
property rights; provided that such termination shall be limited to the countries affected by such injunction. 
 (b) Epizyme
may terminate this Agreement upon providing Abbott ninety (90) days prior written notice if Abbott’s making, having made, importing, exporting, using, distributing, marketing, promoting, offering for sale or selling the Diagnostic Test is
enjoined by a court of competent jurisdiction because such enjoined activity actually or allegedly infringes or misappropriates a Third Party’s intellectual property rights and, during such ninety (90) day period, Abbott is unable or
unwilling to obtain a license to the applicable Third Party intellectual property rights; provided that such termination shall be limited to the countries affected by such injunction. In the event that Epizyme terminates this Agreement pursuant to
this Section 9.4(b), and the injunction that is the basis for such termination is based on actual or alleged infringement or misappropriation for which Abbott is obligated to indemnify Epizyme pursuant to Section 10.2(b), Abbott shall
refund to Epizyme in full (i) all Payment Timetable payment amounts made by Epizyme to Abbott under Sections 5.1 and 5.2 prior to such termination and (ii) all amounts paid by Epizyme to Abbott or to any Third Party under Sections 2.3(b)
and 5.4 prior to such termination, and in addition to the refund amounts described in the foregoing clauses (i) and (ii) Abbott shall pay to Epizyme a termination payment equal to [**] percent of the initially budgeted aggregate Payment
Timetable payment amounts under Section 5.1 (i.e., [**]U.S. Dollars ($[**]). 
 9.5 Elective Termination by Epizyme.
Epizyme may terminate this Agreement upon sixty (60) days written notice to Abbott; provided that, in the event that Epizyme terminates this Agreement pursuant to this Section 9.5 effective after the date eighteen
(18) months following the Effective Date but prior to the completion of the Development Plan, Epizyme shall pay to Abbott a termination fee of [**] U.S. Dollars ($[**]), but shall not pay any other amounts with respect to committed or
uncancelable out-of-pocket Development Plan costs or otherwise. 

  
 28 

 9.6 Survival. Termination of the Agreement for whatever reason in accordance with the
provisions hereof or expiration of this Agreement shall not affect the accrued rights of the Parties, and shall not limit remedies that may be otherwise available in law or equity. Articles 6, 8, 9, 10 and 11 shall survive expiration or termination
of this Agreement for any reason. Survival or termination of the licenses granted in Article 7 shall be governed by the terms set forth in Article 9.7. 
 9.7 Licenses Survive. If Abbott terminates this Agreement for any reason, the licenses and rights granted by Abbott to Epizyme in Section 2.4 and Article 7 shall continue on a fully paid and
perpetual basis. If Epizyme terminates this Agreement for any reason, then (a) the licenses and rights granted by Epizyme to Abbott in Section 2.4 and Article 7 shall continue on a fully paid and perpetual basis, (b) if such
termination occurs prior to the regulatory registration of the Diagnostic Test in any country, the licenses and rights granted by Abbott to Epizyme in Section 7.8 shall continue on a fully paid and perpetual basis, and (c) if such
termination occurs after the regulatory registration of the Diagnostic Test in any country, the licenses and rights granted by Abbott to Epizyme in Section 2.4 and Article 7 shall continue on a fully paid and perpetual basis, provided that any
regulatory or promotional materials used by Epizyme and its permitted assigns and sublicensees in relation to the Diagnostic Test shall be consistent with Epizyme’s and its permitted assigns’ and sublicensees’ package insert for the
Epizyme Product as approved by the applicable Regulatory Authority. 
 9.8 Return of Confidential Information. Upon
expiration or termination of this Agreement for any reason, the Receiving Party shall use reasonable efforts to either return to the Disclosing Party or destroy Confidential Information of the Disclosing Party (including hard and electronic copies
thereof) that is not required by the Receiving Party to exercise surviving license rights as set forth in Section 9.7; provided, however, that the Receiving Party is not required to destroy electronic copies of the Confidential
Information stored in its electronic archive systems, and may retain one (1) copy of such Confidential Information for purpose of complying with its obligations under this Agreement or under Applicable Law. The Receiving Party shall provide
written confirmation that the Receiving Party has complied with its obligations under this Section 9.8 as to such return or destruction of Confidential Information reasonably promptly after termination of the Agreement. 

ARTICLE 10 
 INDEMNIFICATION, LIABILITY LIMITATION AND INSURANCE 

10.1 Indemnification by Epizyme. 
 (a) Subject to Sections 10.3 and 10.4, Epizyme shall indemnify, defend and hold Abbott, its Affiliates, and its and their officers, directors, agents and employees (individually and/or collectively
referred to herein as an “Abbott Party”) harmless from and against any and all losses, liabilities, damages, expenses (including reasonable attorney fees) paid or payable by Abbott or an Abbott Party to a Third Party (collectively,
“Abbott Losses”) to the extent that such Abbott Losses result from or arise in connection with a claim, suit or other proceeding made or brought by a Third Party against Abbott or an Abbott Party (an “Abbott Claim”)
based on, resulting from, or arising in connection with: 
 (i) the breach of any obligation, covenant,
agreement, representation or warranty of Epizyme or an Epizyme Party contained in this Agreement; or 

  
 29 

 (ii) any act or omission by Epizyme, or an Epizyme Party, which constitutes
gross negligence or willful misconduct on the part of Epizyme, or an Epizyme Party; or 
 (iii) any violation of
Applicable Law by Epizyme or an Epizyme Party in connection with the performance of Epizyme’s or its Affiliates’ obligations under this Agreement; or 
 (iv) the development, commercialization or sale of any Epizyme Product; 
 provided,
however, that Epizyme shall not be obligated to indemnify, defend or hold harmless Abbott or an Abbott Party under this Section from any Abbott Claim or for any Abbott Losses incurred by Abbott or an Abbott Party to the extent arising out of or
attributable to: (A) a breach by Abbott, or any Abbott Party of any obligation, covenant, agreement, representation or warranty of Abbott, or any Abbott Party contained in this Agreement; (B) any violation of Applicable Law by Abbott or an
Abbott Party in connection with its obligations under this Agreement; or (C) any act or omission by Abbott or an Abbott Party, which constitutes negligence or willful misconduct on the part of Abbott or an Abbott Party. 

(b) Epizyme shall indemnify, defend and hold harmless Abbott and each Abbott Party from and against all Abbott Losses arising out of any
Abbott Claim alleging infringement by Abbott or Epizyme or misappropriation by Epizyme of a Third Party Patent Right or other intellectual property right by either Party’s importing, exporting, using, distributing, marketing, promoting,
offering for sale or selling of the Epizyme Product or the Diagnostic Test for the Diagnostic Test Intended Use; provided that Abbott shall indemnify, defend and hold harmless Epizyme and each Epizyme Party (and Epizyme shall not
indemnify, defend or hold harmless Abbott or any Abbott Party) as to any infringement or misappropriation that is covered by Section 10.2(b). For the avoidance of doubt, the indemnification, defense and hold harmless obligations of Epizyme
pursuant to this Section 10.1(b) shall not apply to infringement or misappropriation by Abbott’s importing, exporting, using, distributing, marketing, promoting, offering for sale or selling of the Diagnotic Test for any purpose other than
the Diagnostic Test Intended Use. 
 10.2 Indemnification by Abbott. 

(a) Subject to Sections 10.3 and 10.4, Abbott shall indemnify, defend and hold Epizyme, its Affiliates, and Celgene Corporation and its
Affiliates (as licensees or sublicensees of Epizyme with respect to the Epizyme Product under a certain Collaboration and License Agreement dated as of April 2, 2012, as such agreement may be amended from time to

  
 30 

 
time), and its and their officers, directors, agents and employees (individually and/or collectively referred to herein as a “Epizyme Party”) harmless from and against any and
all losses, liabilities, damages, expenses (including reasonable attorney fees) paid or payable by Epizyme or an Epizyme Party to a Third Party (collectively, “Epizyme Losses”) to the extent that such Epizyme Losses result from or
arise in connection with a claim, suit or other proceeding made or brought by a Third Party against Epizyme or an Epizyme Party (a “Epizyme Claim”) based on, resulting from, or arising in connection with: 

(i) the breach of any obligation, covenant, agreement, representation or warranty of Abbott or an Abbott Party contained
in this Agreement; 
 (ii) any act or omission by Abbott or an Abbott Party, which constitutes gross negligence
or willful misconduct on the part of Abbott or an Abbott Party; or 
 (iii) any violation of Applicable Law by
Abbott, or an Abbott Party in connection with the performance of Abbott’s or its Affiliates’ obligations under this Agreement; or 
 provided, however, that Abbott shall not be obligated to indemnify, defend or hold harmless Epizyme or an Epizyme Party from any Epizyme Claim or for any Epizyme Loss incurred by Epizyme or an
Epizyme Party to the extent arising out of, or attributable to: (A) a breach by Epizyme or any Epizyme Party of any obligation, covenant, agreement, representation or warranty of Epizyme or an Epizyme Party contained in this Agreement;
(B) any violation of Applicable Law by Epizyme, or an Epizyme Party in connection with its obligations under this Agreement; or (C) any act or omission by Epizyme, or an Epizyme Party, which constitutes negligence, or willful misconduct on
the part of Epizyme, or an Epizyme Party. 
 (b) [**]. 
 10.3 Indemnification Procedures. 
 (a) Each indemnified Party shall notify
the indemnifying Party in writing (and in reasonable detail) of the Claim within [**] business days after receipt by such indemnified Party of notice of the Epizyme Claim or Abbott Claim, as the case may be, or otherwise becoming aware of the
existence or threatened existence thereof (such Epizyme Claim or Abbott Claim being referred to as a “Claim”). Failure to give such notice shall not constitute a defense, in whole or in part, to any claim by an indemnified Party
hereunder except to the extent the rights of the indemnifying Party are materially prejudiced by such failure to give notice. An indemnifying Party shall have no obligation or liability under this Article 10 as to any Claim for which settlement or
compromise of such Claim, or an offer of settlement or compromise of such Claim, is made by an indemnified Party without the prior written consent of the indemnifying Party, which consent shall not be unreasonably withheld. 

  
 31 

 (b) The indemnifying Party shall assume exclusive control of the defense and settlement
(including all decisions relating to litigation, defense and appeal) of any such Claim; provided, however, that, without the indemnified Party’s prior written consent, which shall not be unreasonably withheld, the indemnifying Party may
not settle such Claim in any manner that would: (i) require payment (unless fully indemnified hereunder) or admission of liability by the indemnified Party; (ii) materially adversely affect the rights granted to the indemnified Party under
this Agreement; (iii) materially conflict with the terms of this Agreement; or (iv) adversely affect other products or services of the indemnified Party or its Affiliates. 

(c) The indemnified Party shall reasonably cooperate with the indemnifying Party, at the Indemnifying Party’s expense, in its
defense of the Claim (including making documents and records available for review and copying and making persons within its control available for pertinent testimony in accordance with the confidentiality provisions of Article 6, and neither Party
shall be required to divulge privileged material to the other). The indemnified Party may participate in, but not control, the defense of such Claim using attorneys of its choice and at its sole cost and expense, with such cost and expense not being
covered by the indemnifying Party. If an indemnifying Party does not assume the defense of the Claim asserted against the indemnified Party, or if the indemnifying Party assumes the defense of the Claim in accordance with Section 10.3 yet fails
to defend or take other reasonable, timely action, in response to such Claim asserted against the indemnified Party, the indemnified Party shall have the right to defend or take other reasonable action to defend its interests in such proceedings,
and shall have the right to litigate, settle or otherwise dispose of any such Claim, without in any way limiting the indemnified Party’s right to be fully indemnified under this Section 10.1 for all Abbott Losses or Epizyme Losses, as
applicable; provided, however, that, without the indemnifying Party’s prior written consent, which shall not be unreasonably withheld, the indemnified Party may not settle such Claim in any manner that would: (i) require payment by
the indemnifying Party; (ii) materially adversely affect the rights granted to the indemnifying Party under this Agreement; (iii) materially conflict with the terms of this Agreement; or (iv) adversely affect other products or
services of the indemnifying Party or its Affiliates. 
 (d) Neither Party will assert any Claim for indemnification under this
Agreement more than two (2) years after the Claim arises. 
 10.4 Liability Limitation. EXCEPT
WITH RESPECT TO A BREACH OF A PARTY’S CONFIDENTIALITY OBLIGATIONS
UNDER ARTICLE 6, OR FOR SUCH DAMAGES THAT MAY BE PAYABLE TO THIRD
PARTIES AND SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 10, IN NO EVENT
WILL EITHER PARTY BE LIABLE TO THE OTHER FOR CONSEQUENTIAL, INDIRECT,
SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES FOR ANY CAUSE OF ACTION, WHETHER
IN CONTRACT, TORT OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, LOST REVENUES,
PROFITS OR BUSINESS OPPORTUNITIES ARISING OUT OF OR IN CONNECTION WITH
THIS AGREEMENT, WHETHER OR NOT THE OTHER PARTY WAS OR SHOULD HAVE
BEEN AWARE OF THE POSSIBILITY OF THESE DAMAGES. 

  
 32 

 10.5 Insurance. 

(a) Abbott hereby represents that it (through its parent company Affiliate, Abbott Laboratories) is self-insured for product liability
and general liability, and that it has and will maintain such coverage for the Term and for a period of [**] years after the expiration of this Agreement or the earlier termination thereof. Such self-insurance is in an amount which is reasonable and
customary in the global medical device and diagnostics industry for companies of comparable size and activities. Abbott further represents that it has and will matintain additional coverage for the term of this Agreement and for a period of [**]
years after the expiration of this Agrement or the earlier termination thereof, in the amounts and types set forth in a certificate of insurance which Abbott has previously provided to Epizyme. 

(b) Epizyme hereby represents that it has and will maintain product liability and general liability coverage for the term of this
Agreement and for a period of [**] years after the expiration of this Agreement or the earlier termination thereof. Such insurance is in an amount which is reasonable and customary in the global pharmaceutical industry for companies of comparable
size and activities to those of Epizyme. 
 ARTICLE 11 

MISCELLANEOUS 
 11.1 Assignment. Neither Party shall assign, or transfer to any Third Party this Agreement or its rights and obligations hereunder without the prior written consent of the other Party, which
consent shall not be unreasonably withheld or delayed, except that Epizyme may assign this Agreement (i) to an Affiliate, or (ii) to a Third Party that acquires the exclusive worldwide rights to develop, market or sell any Epizyme Product
and Abbott may assign this Agreement (i) to an Affiliate or (ii) to a Third Party that acquires the exclusive worldwide rights to develop, market or sell the Diagnostic Test. This Agreement shall be binding upon the successors and
permitted assigns of the Parties. 
 11.2 Counterparts. This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
 11.3
Force Majeure. Neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses on account of failure of performance by the defaulting Party, other than a failure to make payment, if the failure is
occasioned by government action, war, terrorism, fire, explosion, flood, strike, lockout, embargo, shortage of materials or utilities, vendor failure to supply, act of God, or any other cause beyond the control and without the fault or negligence of
the defaulting Party, provided that the Party claiming force majeure has exerted all Commercially Reasonable Efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor
dispute or disturbance. Such excuse shall continue as long as the condition preventing the performance continues. Upon cessation of such condition, the affected Party shall promptly resume performance hereunder. Each Party agrees to give the other
Party prompt written notice of the occurrence of any such condition, the nature thereof, and the extent to which the affected Party will be unable to perform its 

  
 33 

 
obligations hereunder. Each Party further agrees to use all Commercially Reasonable Efforts to correct the condition as quickly as possible and to give the other Party prompt written notice when
it is again fully able to perform its obligations hereunder. 
 11.4 Further Assurances. Each Party hereto agrees to
execute, acknowledge and deliver such further instruments and do all such further acts as may be necessary or appropriate to carry out the purposes and intent of this Agreement. 

11.5 Modification. No waiver, alteration or modification of any of the provisions hereof shall be binding unless made in writing
and signed by the Parties by their respective officers thereunto duly authorized. 
 11.6 Independent Contractors. The
Parties are independent contractors and this Agreement shall not constitute or give rise to an employer-employee, agency, partnership or joint venture relationship among the Parties and each Party’s performance hereunder is that of a separate,
independent entity. 
 11.7 Governing Law; Alternative Dispute Resolution. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York, United States of America, without regard to its conflicts of laws principles. The Parties hereby disclaim the application to this Agreement of the United Nations Convention on the
International Sale of Goods. Any controversy or claim arising from or related to this Agreement or the breach thereof shall be decided pursuant to the Alternative Dispute Resolution set forth in Exhibit I. 

11.8 Headings. Article and section headings in this Agreement are included for convenience of reference and shall not affect the
construction or interpretation of any of the provisions of this Agreement. 
 11.9 Notices. Notices required or permitted
under this Agreement shall be in writing and sent by prepaid registered or certified air mail or by overnight express courier providing evidence of receipt (e.g., Federal Express), and shall be deemed to have been properly served to the
addressee upon receipt of such written communication, to the following addresses of the Parties: 
 If to Abbott: 

Abbott Molecular Inc. 
 Attn: Senior Director, Business Development and Licensing 
 Dept.
09JR 
 1300 East Touhy Avenue 

Des Plaines, Illinois 60018 

  
 34 

 With a copy to: 

Abbott Laboratories 
 Attn: Division Vice President, Commercial Legal Operations 
 Dept.
32MP, Bldg. AP6A-2 
 100 Abbott Park Road 

Abbott Park, Illinois 60064 
 If to Epizyme: 
 Epizyme, Inc. 

Attn: Chief Business Officer 
 400 Technology Square, 4th Floor 
 Cambridge, Massachusetts 02139

 With a copy to: 
 WilmerHale 
 Attn: Steven D. Barrett, Esq. 

60 State Street 
 Boston, Massachusetts 02109 
 11.11 Third Parties. None of the provisions
of this Agreement shall be for the benefit of or enforceable by any Third Party. 
 11.12 Waiver. The waiver by either
Party of a breach or a default of any provision of this Agreement by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any delay or omission on the part of either Party to
exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party. 
 11.13 Severability. If any part of this Agreement is declared invalid by any legally governing authority having jurisdiction over either Party, then such declaration shall not affect the remainder
of the Agreement and the invalidated provision shall be revised in a manner that will render such provision valid while preserving the Parties’ original intent to the maximum extent possible. 

11.14 Entire Agreement. This Agreement (including the exhibits attached hereto) constitutes the entire agreement between the
Parties relating to the subject matter hereof and supersedes all previous writings and understandings including the CDA (as modified pursuant to Section 6.1). 

  
 35 

 *    *    * 

SIGNATURES FOLLOW. 

  
 36 

 IN WITNESS WHEREOF, the Parties by their
respective authorized officers, have executed this Development and Commercialization Agreement on the date first above written. 
  

			
	ABBOTT MOLECULAR INC.
		
	By:	 	 /s/ John Coulter

		
		 	John Coulter, President
	
	EPIZYME, INC.
		
	By:	 	 /s/ Jason Rhodes

		 	Jason Rhodes
	Its:	 	EVP & CBO

 EXHIBIT A(1) 

FISH PLATFORM TECHNOLOGY 

 

			
	 United States Patent Number
	 	 Filing or Issue Date

	[**]	 	
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	
		
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	[**]
	[**]	 	
		
	[**]	 	[**]

 EXHIBIT A(2) 

SPECIFICATIONS 
 EXHIBIT “SPECIFICATIONS” 
 Technical Specifications of MLL
Break Apart FISH Assay 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of
one page was omitted. [**] 

 EXHIBIT B 

DEVELOPMENT PLAN 
  

	 	1.	Objective 

  

	 	•	 	 Develop the Diagnostic Test for clinical studies and launch for commercial sale. 

 

	 	2.	Responsibilities 

 [**]

  

	 	3.	Development Timelines 

The development timeline will be developed and agreed to by the Abbott and Epizyme Project Timeline Leads. 

 

	 	4.	Interactions with US FDA 

Epizyme and Abbott will work together to prepare for and participate in regulatory discussions with FDA. It is likely that several
interactions with US FDA during the development of the test will be required. 
  

	 	5.	Reagent/Component Manufacturing 

 [**]. 
  

	 	6.	Reagent/Assay Development – Cost Breakdown by Activity 

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of three pages were omitted. [**]. 

 Key Assumptions 

 

	•	 	 As of the Effective Date, the following items shall be deemed Key Assumptions which were used to prepare the initial Development Plan, the Regulatory
Plan and the Commercialization Plan and associated Payment Schedule agreed upon by the Parties: 

  

	•	 	 The budget and associated Payment Schedule are estimates based on activities that are currently planned in the long term for support clinical trials
has been provided and are subject to change based on the assumptions listed below and may be modified in the future as the scope of the project becomes more fully defined. Abbott and Epizyme will agree upon modification of the scope and budget of
long-term activities according to the terms of this agreement. 

 Overall Program Assumptions Included in Current Proposal

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of three pages
were omitted. [**]. 

 EXHIBIT C 

REGULATORY PLAN 
 Epizyme and Abbott will actively cooperate in the regulatory process for the development and global regulatory registration of the Diagnostic Test. The regulatory process includes the development of
regulatory strategy, the sharing of regulatory information and data and the submission and liaison with global Regulatory Authorities. Abbott will serve as the formal sponsor of any submissions to global Regulatory Authorities that pertain to the
Diagnostic Test, and therefore will be ultimately responsible for the submission of such required documentation per the jointly agreed timelines; provided, however, that the preparation, including strategy, for such submissions will be done
in cooperation and consultation with Epizyme and Epizyme shall have the right to attend and participate in all meetings between Abbott and Regulatory Authorities relating to the co-development of the Diagnostic Test. Activities included in the
regulatory process that are subject to this regulatory plan include the following: 
  

	 	•	 	 Routine interactions of Abbott and Epizyme regulatory representatives to share regulatory information relevant to the agreed strategy for development
and registration of the Diagnostic Test. 

  

	 	•	 	 Abbott will inform Epizyme about any inspections from Regulatory Authorities related to the Diagnostic Test and will provide reports of any findings to
Epizyme. 

  

	 	•	 	 [**]. 

  

	 	•	 	 [**]. 

  

	 	•	 	 [**]. 

  

	 	•	 	 Epizyme and Abbott will jointly develop a timeline and priority list for regulatory submissions. The timeline will include submission dates and
anticipated approval dates for both the Diagnostic Test and the Epizyme Product. 

 As a part of the regulatory plan regarding
the timelines for regulatory submissions and target timelines for approval, [**]: 
 Confidential Materials omitted and filed
separately with the Securities and Exchange Commission. A total of one page was omitted. [**]. 

 EXHIBIT D 

COMMERCIALIZATION PLAN 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of six pages were omitted. [**]. 

 EXHIBIT E 

PAYMENT SCHEDULE 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of one page was omitted. [**]. 

 EXHIBIT F 

GOVERNANCE OF AGREEMENT 

 
 

 

 EXHIBIT G 

GOVERNANCE ESCALATION PROCESS 

 
 

 

 EXHIBIT H 

GOVERNANCE ROLES AND RESPONSIBILITIES 

 
 

 

 EXHIBIT H 

GOVERNANCE ROLES AND RESPONSIBILITIES
CON’T 
  

 

 

 EXHIBIT H 

GOVERNANCE ROLES AND RESPONSIBILITIES
CON’T 
  

 

 

 EXHIBIT I 

ALTERNATIVE DISPUTE RESOLUTION 

The parties recognize that a bona fide dispute as to certain matters may arise from time to time during the term of this Agreement which relates to
either party’s rights and/or obligations. To have such a dispute resolved by this Alternative Dispute Resolution (“ADR”) provision, a party first must send written notice of the dispute to the other party for attempted resolution by
good faith negotiations between their respective representatives of the affected subsidiaries, divisions, or business units within [**] days after such notice is received (all references to “days” in this ADR provision are to calendar
days). 
 If the matter has not been resolved within [**] days of the notice of dispute, or if the parties fail to meet within such [**] days,
either party may initiate an ADR proceeding as provided herein. The parties shall have the right to be represented by counsel in such a proceeding. 
 1. To begin an ADR proceeding, a party shall provide written notice to the other party of the issues to be resolved by ADR. Within [**] days after its receipt of such notice, the other party may, by
written notice to the party initiating the ADR, add additional issues to be resolved within the same ADR. 
 2. Within [**] days following
receipt of the original ADR notice, the parties shall select a mutually acceptable neutral to preside in the resolution of any disputes in this ADR proceeding. If the parties are unable to agree on a mutually acceptable neutral within such period,
the parties shall request the President of the Center for Public Resources (“CPR”), 366 Madison Avenue, New York, New York 10017 to select a neutral pursuant to the following procedures: 

(a) The CPR shall submit to the parties a list of not less than five (5) candidates within [**] days after receipt of the request
from the parties, along with a Curriculum Vitae for each candidate. No candidate shall be an employee, director, or shareholder of either party or any of their subsidiaries or affiliates. 

(b) Such list shall include a statement of disclosure by each candidate of any circumstances likely to affect his or her impartiality.

 (c) Each party shall number the candidates in order of preference (with the number one (1) signifying the greatest
preference) and shall deliver the list to the CPR within [**] days following receipt of the list of candidates. If a party believes a conflict of interest exists regarding any of the candidates that party shall provide a written explanation of the
conflict to the CPR along with its list showing its order of preference for the candidates. Any party failing to return a list of preferences on time shall be deemed to have no order of preference. 

(d) If the parties collectively have identified fewer than three (3) candidates deemed to have conflicts, the CPR immediately shall
designate as the neutral the candidate for whom the parties collectively have indicated the greatest preference. If a tie should result 

 
between two candidates, the CPR may designate either candidate. If the parties collectively have identified three (3) or more candidates deemed to have conflicts, the CPR shall review the
explanations regarding conflicts and, in its sole discretion, may either (i) immediately designate as the neutral the candidate for whom the parties collectively have indicated the greatest preference, or (ii) issue a new list of not less
than five (5) candidates, in which case the procedures set for in subparagraphs 2(a) - 2(d) above shall be repeated. 
 3. No earlier than
[**] days or later than [**] days after selection, the neutral shall hold a hearing to resolve each of the issues identified by the parties. The ADR proceeding shall take place at a location agreed upon by the parties. If the parties cannot agree,
the neutral shall designate a location other than the principal place of business of either party or any of their subsidiaries or affiliates. 

4. At least [**] days prior to the hearing, each party shall submit the following to the other party and the neutral: 

(a) a copy of all exhibits on which such party intends to rely in any oral or written presentation to the neutral; 

(b) a list of any witnesses such party intends to call at the hearing, and a short summary of the anticipated testimony of each witness;

 (c) a proposed ruling on each issue to be resolved, together with a request for a specific damage award or other remedy for
each issue. The proposed rulings and remedies shall not contain any recitation of the facts or any legal arguments and shall not exceed [**] per issue. 
 (d) a brief in support of such party’s proposed rulings and remedies, provided that the brief shall not exceed [**] pages. This page limitation shall apply regardless of the number of issues raised
in the ADR proceeding. 
 Except as expressly set forth in subparagraphs 4(a) - 4(d) above, no discovery shall be required or
permitted by any means, including depositions, interrogatories, requests for admissions, or production of documents. 
 5. The hearing shall be
conducted on [**] consecutive days and shall be governed by the following rules: 
 (a) Each party shall be entitled to [**]
hours of hearing time to present its case. The neutral shall determine whether each party has had the [**] hours to which it is entitled. 
 (b) Each party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents or other evidence, to cross-examine witnesses, and to make a closing
argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examination time shall be charged against the party conducting the cross-examination. 

 (c) The party initiating the ADR shall begin the hearing and, if it chooses to make an
opening statement, shall address not only issues it has raised but also any issues raised by the responding party. The responding party, if it chooses to make an opening statement, also shall address all issues raised in the ADR. Thereafter, the
presentation of regular and rebuttal testimony and documents, other evidence, and closing arguments shall proceed in the same sequence. 
 (d) Witnesses shall be excluded from the hearing until closing arguments. 
 (e)
Neither affidavits nor settlement negotiations shall be admissible under any circumstances. As to all other matters, the neutral shall have sole discretion regarding the admissibility of any evidence. 

6. Within [**] days following completion of the hearing, each party may submit to the other party and the neutral a post-hearing brief in support of its
proposed rulings and remedies, provided that such brief shall not contain or discuss any new evidence and shall not exceed [**] pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. 

7. The neutral shall rule on each disputed issue within [**] days following completion of the hearing. Such ruling shall adopt in its entirety the
proposed ruling and remedy of one of the parties on each disputed issue but may adopt one party’s proposed rulings and remedies on some issues and the other party’s proposed rulings and remedies on other issues. The neutral shall not issue
any written opinion or otherwise explain the basis of the ruling. 
 8. The neutral shall be paid a reasonable fee plus expenses. These fees and
expenses, along with the reasonable legal fees and expenses of the prevailing party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows:

 (a) If the neutral rules in favor of one party on all disputed issues in the ADR, the losing party shall pay 100% of such fees
and expenses. 
 (b) If the neutral rules in favor of one party on some issues and the other party on other issues, the neutral
shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the parties. The neutral shall allocate fees and expenses in a way that bears a reasonable relationship to the outcome of the ADR, with
the party prevailing on more issues, or on issues of greater value or gravity, recovering a relatively larger share of its legal fees and expenses. 
 9. The rulings of the neutral and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be entered as a final judgment in any court having jurisdiction.

 10. Except as provided in paragraph 9 of this Exhibit or as required by law, the existence of the dispute,
any settlement negotiations, the ADR hearing, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed Confidential Information. The neutral shall have the authority to impose sanctions for
unauthorized disclosure of Confidential Information. 
 11. The neutral may not award punitive damages. The parties hereby waive the right to
punitive damages. 
 12. The hearings shall be conducted in the English language in Boston, Massachusetts.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]